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Immune tolerance mechanisms prevent the development of immune responses 
directed to the host. This is especially important for the adaptive immune system, 
whose potent and long-lasting responses would be extremely deleterious to the host if 
misguided. This work explores two aspects of immune tolerance: the role of protein O-
GlcNAcylation in regulatory T (Treg) cells and the importance of interferons during T 
cell tolerance development in the thymus. 
 
In chapter 2 of this document, we show that the posttranslational modification by 
O-linked N-Acetylglucosamine (O-GlcNAc) stabilizes FOXP3 and activates STAT5, 
thus integrating these critical signaling pathways. O-GlcNAc-deficient Treg cells 
developed normally but displayed modestly reduced FOXP3 expression, strongly 
impaired lineage stability and effector function, and ultimately fatal autoimmunity in 
mice. Moreover, deficiency in protein O-GlcNAcylation attenuated IL-2/STAT5 
signaling, while overexpression of a constitutively active form of STAT5 partially 
ameliorated Treg cell dysfunction and systemic inflammation in O-GlcNAc deficient 
mice. These data demonstrate that protein O-GlcNAcylation is essential for lineage 
stability and effector function in Treg cells. 
 
In chapter 3, we characterize the expression of interferons in the thymus. We 
found that developing thymocytes displayed a type I IFN signature that was mainly 
dependent on IFN-β. Using Ifnb tdtomato and luciferase reporter mouse strains, we 
found expression in a small population of medullary thymic epithelial cells (mTEC), 
which was AIRE dependent and peaked at 2-3 weeks of age. To study the cellular 
response to thymic interferon, we used an Mx1gfp reporter mouse strain and report that 
numerous thymic cell populations respond constitutively to IFN in vivo. The response in 
some cell populations was not abrogated unless both IFNR and IFNR, or STAT1 
were deficient, suggesting that both type I and type III IFNs are at play. Indeed, single 
cell RNA sequencing analysis revealed dramatic transcriptional changes in all thymic 
APCs in IFNR/ IFNR deficient mice. These results show that steady state type I and 
type III IFN signaling drives a gene-expression program in thymic APCs that shapes 
the thymic microenvironment.  
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Chapter 1 Introduction 
  
 2 
1.1 T cell tolerance 
 
The immune system provides a powerful defense against infections and cancer. 
However, there are mechanisms of immune tolerance in place to prevent immune 
responses against the body’s own cells. When these mechanisms fail, disorders like 
autoimmune diseases may develop. 
 
In vertebrates, which have a highly specific adaptive immune system, immune 
tolerance mechanisms are complex and involve the control of lymphocyte responses 
against healthy host cells. The expression of antigen receptors - which are randomly 
generated by recombination - in lymphocytes represents a particular challenge for the 
development of tolerance by the adaptive immune system. Specifically in T 
lymphocytes, the somatic gene rearrangements of T-cell antigen receptors (TCRs) 
afford protection against a vast number of pathogens but also generate some TCRs 
that are either useless or have the potential to recognize self-antigens. Tolerance 
mechanisms ensure that potentially autoreactive TCRs do not cause any damage. 
 
T cell tolerance guarantees that the T cell repertoire remains unresponsive to 
every self-antigen expressed in the body. This includes not only ubiquitously expressed 
self-antigens but also self-antigens that have different expression patterns. For 
instance, tolerance should develop to self-antigens that are normally expressed in 
specific peripheral tissues, or during a specific stage of the development of the 
organism, or during transient processes like inflammation or tissue repair. 
 
When T cell tolerance mechanisms operate during T cell development in the 
thymus they are referred to as “central tolerance, whereas if they occur during 
circulation on mature T cells, they are termed “peripheral tolerance”. 
1.1.1 Central Tolerance 
T cell progenitors develop in the bone marrow and migrate to the thymus, 
where they randomly rearrange their TCR  and  genes. Once expressing a functional 
TCR on their surface, CD4 and CD8 double-positive (DP) thymocytes interact with self-
peptide-major histocompatibility complexes (MHC) displayed on cortical thymic 
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epithelial cells (cTEC). If there is a low-affinity interaction, thymocytes receive survival 
signals and differentiate into CD4- and CD8-single positive (SP) cells – a process 
known as positive selection 1. 
 
1.1.1.1 Clonal Deletion 
Thymocytes with TCRs that interact strongly with self-peptide-MHC complexes 
are potentially autoreactive and could cause damage if allowed in the periphery, thus 
many of these clones are removed from the repertoire through a mechanism known as 
clonal deletion, whereby cell death is induced by apoptosis. Most deletion events take 
place in the cortex at the DP stage, and during the SP stage, thymocytes migrate to the 
medullary region, where their interactions with an extensive network of different 
antigen-presenting cells (APCs) can also result in clonal deletion 2.  
 
Among the APCs that mediate clonal deletion, medullary thymic epithelial cells 
(mTEC) are critical. This is because of their exceptional capacity to express tissue-
restricted antigens (TRAs), a process mediated mainly by specialized transcriptional 
factors such as the autoimmune regulator (AIRE) 3 and Fezf2 4.  
Dendritic cells (DC) also mediate clonal deletion in the thymus 5. Three main subsets of 
thymic DCs have been described: plasmacytoid DC (pDCs), XCR1+ cDC1, and 
SIRP+ cDC2 6. The relative contribution of DCs to clonal deletion is large since they 
are distributed both in the cortex and the medulla, can “cross present” antigens, and 
express high amounts of co-stimulatory molecules. 
Thymic B cells, located mainly in the medulla and the cortico-medullary region, 
have also been shown to contribute to clonal deletion 7–9. They express high amounts 
of MHC and co-stimulatory molecules, which likely results in a greater ability to present 
antigens. Some thymic B cells also express Aire 10, which allows them to present a 
diverse set of self-antigens, while others present antigens that have been acquired with 
their B cell receptor (BCR) 11. 
 
Although numerous thymic APCs can mediate clonal deletion, not all self-
reactive T cell clones are removed from the repertoire. Some of these T cells with 
autoreactive potential can differentiate into regulatory T (Treg) cells, which mediate 
tolerance mainly through the suppression of other cells. The factors that determine 
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whether a self-reactive T cell clone is deleted or becomes a Treg cell are complex and 
will be discussed below. 
 
1.1.1.2 Regulatory T cell differentiation 
Recognition of self-antigens during T cell development can also result in the 
differentiation of forkhead box protein P3 (FOXP3)+ Treg cells. Treg cells are essential 
to maintaining immune tolerance and homeostasis 12,13. As opposed to the cell-intrinsic 
recessive tolerance mediated by mechanisms like clonal deletion, the tolerance 
provided by Treg cells is dominant, meaning that they actively exert suppressive and 
regulatory functions on other cells. The specific signals and conditions that determine a 
Treg cell fate will be discussed in the sections below. 
 
Most of the thymic APCs that mediate clonal deletion, are also involved in 
delivering signals for Treg differentiation. In mTECs, Aire plays an important role in the 
development of tissue-specific Treg cells 14. Both cDC1 and cDC2 also contribute to 
Treg cell induction by providing antigens and cytokines to self-specific T cell clones 
15,16. Finally, B cells have recently been involved in Treg cell differentiation through their 
expression of MHC and co-stimulatory molecules 17,18. 
 
Although most self-reactive T cells are either eliminated or become Treg cells in 
the thymus, some are not controlled by central tolerance mechanisms and make it out 
of the thymus into the circulation. To limit the expansion and reactivity of these T cells 
in peripheral tissues, there are mechanisms of peripheral tolerance in place. 
1.1.2 Peripheral Tolerance 
Several peripheral tolerance checkpoints exist to regulate the self-reactive 
potential of T cells within lymphoid and non-lymphoid tissues. Some of them are cell-
intrinsic and operate directly within the responding T cells and some are T cell-extrinsic 
and involve other cell populations acting on the self-reactive T cells 19. 
 
1.1.2.1 Cell-intrinsic tolerance mechanisms 
Numerous cell-intrinsic mechanisms maintain mature self-reactive T cells in an 
unresponsive state. For instance, quiescence 20–22 and ignorance 23 operate on naïve T 
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cells and make sure that they maintain a G0 stage of the cell cycle or just fail to get 
activated by avoiding getting in contact with the cognate antigen, respectively.  
 
Anergy is a very well-studied mechanism that results in a state of 
hyporesponsiveness after TCR stimulation. This occurs when co-stimulation is deficient 
during TCR engagement 24. Anergy is regulated at the epigenetic 25 and post-
translational 26 levels and can be reversed under certain conditions 27,28. 
 
T cell exhaustion is an additional non-deletional mechanism that operates on T 
cells during their effector stage, well after undergoing productive activation. This 
mechanism tends to occur in the context of chronic TCR stimulation 29 and results in T 
cells with strongly reduced responses to antigen encounters 30. 
 
Finally, tolerance can be mediated through senescence, a state where the 
replicative potential of the T cell is lost. This can occur under certain circumstances 
such as repeated TCR stimulation, stimulation by certain cytokines 31, or simply with 
aging 32. Senescence can be explained by telomere erosion but there might be other 
telomer-independent mechanisms at play 19.  
 
1.1.2.2 Cell-extrinsic tolerance mechanisms 
In some cases, peripheral cells can actively induce and maintain tolerance in T 
cells. An example of this is DC-mediated tolerance, in which tolerogenic immature DCs 
present antigens to T cells without delivering proper co-stimulation. These DC 
populations express low levels of both MHC and costimulatory molecules but have an 
increased capacity for endocytosis and phagocytosis 33. They also produce several 
immunosuppressive factors such as TGF-, IL-10, and corticosteroids, which promote 
T cell anergy 34–36, Treg differentiation 37–40, or even T cell apoptosis 33. 
 
The other main cell population that maintains peripheral immune tolerance is 
Treg cells. As mentioned in the previous sections, most Treg cells develop in the 
thymus. However, under specific circumstances, some Treg cells can arise in the 
periphery – these are called pTreg cells. The presence of TGF- during the activation 
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of naïve T cells is a critical factor for pTreg cell induction. This occurs mainly in the 
gastrointestinal tract but can happen in other tissues such as the skin and the liver 41. 
 
Regardless of their origin, Treg cells are functionally diverse and versatile in the 
periphery. Some populations of Treg cells, called central Treg (cTreg) cells populate, 
lymphoid tissues and are more quiescent, whereas effector Treg (eTreg) cells seem to 
be further differentiated, express activation markers, and have a higher suppressive 
capacity. Furthermore, eTreg cells acquire specific functions and characteristics that 
are specific to the tissues that they reside 42.  
1.2 Clonal deletion versus Treg cell differentiation 
 
Self-reactive T cell fate after cognate antigen encounter is determined by several 
factors. One of them is the nature of the TCR-peptide-MHC interaction, which is 
determined by its affinity and/or avidity. However, other variables influence the 
outcome such as the modality of the self-antigen expression and presentation, the 
presence of co-stimulation and additional cytokine signals, and even the 
developmental stage of the T cell at the moment of TCR engagement 43. 
1.2.1 T cell developmental stage 
T cells move through several stages of development in a well-regulated 
manner, and it is thought that each stage influences the susceptibility to undergo either 
clonal deletion or Treg cell differentiation. DP thymocytes are extremely sensitive to 
antigen and seem to have a lower threshold to elicit clonal deletion compared to SP 
thymocytes, despite their comparatively low levels of TCR expression 44,45. At the same 
time, the susceptibility to become a Treg cell might come around the time of CD4+ 
lineage commitment and might be mediated by cell-intrinsic signals occurring after the 
DP stage, and extrinsic signals present only in the medulla, where SP thymocytes are 
predominant 43. 
1.2.2 Nature of the TCR stimulus 
Both the strength (affinity) and the number of interactions (avidity) between the 
TCR and the self-antigen-MHC complex are important for the outcome of the T cell. 
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Stronger interactions and increasing antigen density tend to favor clonal deletion over 
Treg cell differentiation. Recent evidence from tetramer-based studies on polyclonal 
populations suggests that ubiquitously expressed self-antigens elicit clonal deletion, 
whereas less abundant self-antigens, like TRAs, favor the development of Treg cells 
46,47. In support of this, Treg cells are important players in the tolerance developed to 
AIRE-dependent TRAs 5,48. Interestingly, these experiments also indicate that clonal 
deletion and Treg cell differentiation can occur in parallel for the same self-antigen. 
 
Self-antigen expression patterns might also influence the number of interactions 
that a single T cell has with APCs, thus impacting the outcome. Highly expressed self-
antigens might promote a single and sustained interaction that likely results in 
apoptotic signals being delivered to the T cell, whereas a TRA-like expression pattern 
might result in discontinuous TCR engagement with several APCs, which in turn will 
promote Treg cell differentiation 43. 
1.2.3 Co-stimulation and soluble factors 
Non-antigenic signals during TCR-self-peptide-MHC interactions can also 
impact how T tolerance is developed. They can come from co-stimulatory molecules or 
cytokines and will be described below. 
 
1.2.3.1 IL-2 
In addition to TCR stimulation, the availability of IL-2 is vital for Treg cell 
development. TCR-self-peptide-MHC interactions of intermediate strength initiate Treg 
cell commitment by either inducing the expression of CD25 (a chain of the high-affinity 
IL-2 receptor) or upregulating the transcription factor FOXP3 to generate CD25+ or 
FOXP3lo Treg cell precursors, respectively. Both of these precursors require IL-
2/STAT5 survival signals to complete their differentiation into mature CD25+ FOXP3+ 
Treg cells 49. 
 
The availability of IL-2 is determined by the cell sources and competition 
between developing Treg cells. Thymic DCs may provide some IL-2 but the main cell 
sources are T cells themselves, with CD4+ SP thymocytes or recirculating T cells being 
the most likely 50. Competition for IL-2 can result in mature Treg cells limiting the 
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availability of IL-2 for Treg cell precursors, thus inhibiting de novo differentiation. 
Recently, recirculating Treg cells have also been proposed to limit Treg cell 
differentiation through the same mechanism 51. 
 
1.2.3.2 CD28 
The role of co-stimulation through CD28 in the type of tolerance induced in T 
cells is not completely understood. It is clear that the absence of CD28, or its ligands 
CD80 and CD86, results in a reduced compartment of Treg cells 52. CD28 might 
negatively regulate death signals in Treg cell precursors, thus allowing an efficient 
development of the Treg cell compartment 53,54, however, the molecular mechanisms 
are not well defined. Interestingly, CD28 can also adopt a different role and favor clonal 
deletion. The requirement of CD28 for clonal deletion has been described in in vitro 
experiments 55, superantigen-mediated T cell death 56, and at the polyclonal level under 
physiologic conditions 2. Recently, it has been proposed that the CD28 signaling 
domain requirements for Treg cell differentiation and clonal deletion are different and 
that these two outcomes can widely vary depending on the TCR specificity and the 




Although the role of TGF- for the conversion of naïve T cells into pTreg cells is 
relatively well-established, its importance during thymic Treg cell development is not as 
clear. TGF- does appear to restrain clonal deletion in favor of Treg cell differentiation, 
but whether this is the result of merely pro-survival signals or differentiation cues, is not 
understood 43. 
 
1.2.3.4 TNFR superfamily members (TNFRSF) 
TCR engagement coupled with CD28 co-stimulatory signals also upregulate the 
expression of three TNFRSF members: OX40, GITR, and TNFR2. The level of 
expression of these receptors correlates with the strength of TCR stimulation and their 
engagement results in an increased IL-2 sensitivity by developing Treg cells, thereby 




Protein post-translational modifications regulate the signaling networks required 
for Treg cell differentiation and stability. Phosphorylation, acetylation, and ubiquitination 
are some of the modifications that occur in several signaling molecules that mediate 
Treg cell stability and function 59. A novel modification consisting of the addition of O-
linked N-Acetylglucosamine (O-GlcNAc) to serine and threonine residues has been 
described in numerous cell populations. O-GlcNAcylation modifies thousands of 
proteins, and we studied its role in the integration of important molecular signals for 
Treg cells 60. Indeed, we found that O-GlcNAcylation was essential for the stability and 
function of both TCR-derived signals, like FOXP3, and IL-2-related mediators like 
STAT5. These findings are presented in chapter 2 of this dissertation. 
1.3 Antigen presentation during T cell tolerance development 
 
The efficiency of T cell tolerance is closely correlated with the availability of self-
antigens during development. Thus, the way antigens are processed and presented in 
the context of MHC class I and MHC class II greatly influences the outcome of 
tolerance. This depends on a variety of variables like the type of APC delivering the 
antigen, the maturation status of the APC, and the presence of soluble factors. Indeed, 
there is no evidence that distinct APCs selectively promote either clonal deletion or 
Treg cell differentiation, instead, it is clear that most thymic APCs can induce both 
forms of tolerance 61 and that, for the establishment of optimal immune tolerance, they 
should all together present the entire repertoire of self-antigens (peptidome) that T cells 
are likely to encounter later in life. The major APC populations in the thymus will be 
described below. 
1.3.1 Major APCs in the thymus 
1.3.1.1 Medullary thymic epithelial cells (mTECs) 
mTECs are highly specialized APCs that are vital for the development of T cell 
tolerance. They have a unique promiscuous gene expression that allows them to 
express numerous TRAs. As stated in previous sections, this is partly due to the 
expression of Aire and the recently described transcription factor Fezf2. In addition to 
TRAs, Aire drives the expression of co-stimulatory molecules like CD80 in mTECs. In 
fact, mutations in the Aire gene lead to autoimmune poly-endocrinopathy candidiasis 
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ectodermal dystrophy syndrome (APECED) in humans 62. Furthermore, mTECs 
express CCL19 and CCL21, chemokine ligands that attract CCR7-expressing 
thymocytes to the medullary region 63. 
 
AIRE-deficient animals have slightly higher numbers of CD4SP specific for a 
certain antigen, which suggests that mTEC can enable T cell tolerance through clonal 
deletion 62. However, recent TCR repertoire analyses have shown that the expression 
pattern of TRAs in mTECs also promotes Treg cell differentiation 5,48. 
 
1.3.1.2 Conventional dendritic cells (cDC) 
Thymic DCs are ontogenically and functionally diverse. Conventional type I 
DCs (cDC1) express CD8a and XCR1 and get recruited to the medulla by XCL1-
expressing mTECs in an AIRE-dependent manner 64. This mTEC-cDC1 interaction 
may result in cross-presentation of mTEC-derived self-antigens by cDC1. 
 
Thymic conventional type 2 DCs (cDC2) migrate from the periphery into the 
thymus as mature DCs. Their recruitment is mediated by their CCR2 expression and 
CCL8 expression by mTECs. Interestingly, cDC2s express SIRP and can acquire and 
transport self-antigens into the thymus 65, which opens the possibility that they mediate 
tolerance to extrathymic antigens. 
 
1.3.1.3 B cells 
B cells localize to the medulla and the cortico-medullary junction, where they 
mediate T cell tolerance. Although their origin is still unclear, there is evidence that B 
cells could both develop in the thymus and recirculate from the periphery 61. Compared 
to splenic B cells, thymic B cells have increased expression of MHC class II and co-
stimulatory molecules 10,18, which suggests a higher antigen presentation capacity. 
Interestingly, some B cells, like mTECs, express Aire and some TRAs 10, but the exact 
role of Aire in B cells is still being investigated. 
 
Thymic B cells interact with developing thymocytes and receive CD40 
stimulation, which is required for their maintenance 7. These cognate interactions are 
indeed important for tolerance development. The absence of B cells in the thymus 
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reduces the frequency of thymic Treg cells 17,18. Furthermore, B cells can also promote 
clonal deletion to endogenous antigens and exogenous antigens acquired via their B 
cell receptor (BCR). Class switching, mediated by the activation-induced cytidine 
deaminase (AID), is also common in thymic B cells, and the absence of this enzyme 
increases the number of autoreactive T cells 66, which indicates that these class-
switched B cells are important for T cell tolerance development. 
 
1.3.1.4 Monocyte/Macrophages cells 
Because of their heterogeneity and complex ontogeny, non-DC myeloid cells in 
the thymus have not been studied in detail. Regardless of their origin, it is clear that a 
subset of thymic macrophages plays an essential role in the clearance of the numerous 
apoptotic cells that result from positive and negative selection 67,68. Additionally, 
monocytes and monocyte-derived cells, which together with macrophages can be 
referred to as mononuclear phagocytes 69, have been described in the thymus. As is 
the case in many tissues, there are LY6Chi classical monocytes as well as LY6Clow 
non-classical monocytes in the thymus. Recently, a study identified a CD14+ monocyte-
derived DC population that acquires mTEC-derived antigens and promotes T cell 
tolerance through Treg cell differentiation 70. 
1.3.2 Maturation status of thymic APCs 
Some thymic APCs can undergo maturation, which may provide signals that 
allow for a more efficient tolerance establishment. The best-described case is for 
cDC1, which undergo constant homeostatic maturation in the thymus characterized by 
the upregulation of the chemokine receptor CCR7, MHC class II, CD40, and co-
stimulatory molecules. Mature cDC1 acquire the capacity to cross-present mTEC-
derived antigens 71. 
 
In humans, studies have shown the importance of thymic stromal lymphopoietin 
(TSLP), produced by epithelial cells of the Hassall’s corpuscles, for the maturation of 
cDCs and pDCs 72,73. This maturation was characterized by increased expression of 
co-stimulatory molecules and efficient Treg cell induction. Recent data from human 
single-cell RNA sequencing studies indicate that maturation occurs in both cDC1 and 
cDC2 and significantly changes gene expression, increases the expression of 
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chemokines and co-stimulatory molecules, and induces the expression of transcription 
factors like Aire and FOXD4 74. 
1.3.3 Interferon and antigen processing and presentation 
Soluble factors like interferons (IFNs) can greatly affect antigen processing and 
presentation (as will be shown below), and if present in the thymus, could drastically 
influence T cell tolerance establishment. There are three major IFN families. Type I 
IFNs (IFN-I) bind to the IFN-α/ receptor (IFNAR) and are composed of 14 IFN-α 
subtypes in mice (13 in humans), one IFN-, and other minor subtypes. Type II IFN 
(IFN-II) consists of IFN-γ only and binds to a specific receptor IFNGR. Type III IFNs 
(IFN-λ or IFN-III) are the most recently described; there can be 2 to 4 subtypes 
depending on the species, and they bind to the IFNLR (see Figure 1.1). 
 
1.3.3.1 IFN gamma 
The gene expression levels of MHC class II are tightly regulated mainly by the 
MHC class II transactivator (CIITA), which is constitutively expressed only in 
professional APCs, and its activity can respond to environmental cues 75. It is well 
known that IFN-γ controls CIITA expression and thus the upregulation of MHC class II 
76. Analogously, the protein NLRC5 transcriptionally activates MHC class I genes and 
acts as an MHC class I transactivator (CITA) 77. NLRC5 is highly responsive to IFN-γ. 
IFN-γ-treated APCs also display high levels of constitutive autophagy and efficient 
delivery of endogenous antigens to MHC class II-expressing compartments 78. Several 
mechanisms have been proposed to explain this activation of autophagy 79. Finally, 
IFN-γ plays an important role in the regulation of antigen processing and presentation 
by MHC class I. IFN-γ not only induces the expression of several proteasome subunits 
and modulates their activity, but also stimulates the expression of additional proteases, 
which together modulates the efficiency and quality of antigen processing and 
presentation 80–82.  
 
1.3.3.2 Type I IFNs 
There are numerous ways IFN-I may modulate antigen processing and 
presentation. For example, in immature DCs and monocytes, IFN-α/β stimulation, like 
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IFN, upregulates the expression of MHC molecules (class I and II) and co-stimulatory 
molecules CD80 and CD86 83–85. 
 
IFNs-I are also important for efficient cross-presentation by DCs, which allows 
them to load exogenous peptides into MHC class I molecules. This is important in both 
infections and cancer. The cross-presentation capacity of murine DCs lacking IFNAR is 
greatly reduced, which results in their inability to reject tumors 86,87. The importance of 
IFN-I in cross-presentation has also been extensively assessed during viral infections 
in both mice and humans 88–91. Furthermore, IFN-I can also modulate the expression of 
some proteasome subunits 92,93, and, similar to IFN-γ, can induce the expression of 
CITA 94. 
 
The role of IFN-I is also key for antigen processing and presentation through 
MHC class II. For instance, IFN-α/β promotes a type of maturation in DCs that, unlike 
TLR-dependent maturation, results in continued MHC class II synthesis and antigen 
processing 95. Additionally, IFN-I induce the production of CXC-chemokine ligand 9 
(CXCL9) and CXCL10 by APCs, which can attract T cells and facilitate TCR-self-
peptide-MHC interactions 96. Finally, autophagy, which promotes MHC class II 
presentation of self-peptides, is induced by IFN-I 97,98. 
 
IFN-I also have direct and indirect effects on B cells, which could modify the 
antigens they present. For instance, IFN-I induce the expression of B cell-activating 
factor (BAFF) and a proliferation-inducing ligand (APRIL) in DCs, molecules that 
enhance class switching in B cells 99,100. IFN-I can also enhance antibody responses 
and subclass switching directly on B cells 101, which potentially results in the 
presentation of activation-dependent self-antigens. 
 
1.3.3.3 Type III IFNs 
While IFN-λs and IFN-α/β are induced by similar pathways and activate related 
gene expression programs, it is becoming clear that they also have non-redundant 
functions in mediating protection, especially in the context of mucosal and barrier 
surfaces 102. Recent studies on the capacity of IFN-III to modulate immune responses 
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indicate that these molecules might also have strong effects on antigen processing and 
presentation. 
 
The biological activity of IFN-λs in mice was initially thought to be restricted to 
epithelial cells, but numerous studies have shown potent effects on B cells, DCs, 
neutrophils, among others 103. Studies on IFNLR-deficient bone marrow-derived DCs 
(BMDCs) suggest reduced maturation and antigen processing 104. Interestingly, 
quantitative proteomics analyses of IFN-λ-stimulated cells indicate the upregulation of 
several molecules involved in antigen processing and presentation, including subunits 
of the immunoproteasome 105. 
 
 
Figure 1.1. Canonical interferon signaling pathways.  
The three different types of IFN bind to different receptors. IFN-I bind to IFNAR (IFNAR1 and 
IFNAR2) whereas IFN-III bind to IFNLR (IL10Rβ and IFNLR1); both of these receptors activate 
the tyrosine kinases JAK1 and TYK2, eventually leading to the recruitment of STAT1 and 
STAT2. Heterodimers of STAT1 and STAT2 can bind to IRF9 to form the interferon-stimulated 
gene factor 3 (ISGF3) complex, which bind to interferon-stimulated response elements (ISREs) 
in interferon stimulated genes (ISGs) to activate their transcription. Homodimers of STAT1 can 
translocate into the nucleus and bind γ-activated sequence (GAS) promoter elements in ISG to 
induce their transcription. IFN-II binds to the IFNGR (two chains of IFNGR1 and two of IFNGR2) 
to activate JAK1 and JAK2, leading to the recruitment and activation of homodimers of STAT1, 
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which will then bind GAS elements in the nucleus. These are the canonical pathways, but 
additional signaling pathways might get activated by IFNs. Created in BioRender.com. 
 
Because some of the gene changes induced by IFN (like proteosome subunits and 
autophagy genes) alter the specificity of self-peptide processing and presentation, IFN 
treatment of APC not only increases, but changes, the displayed self-peptidome. For 
example, in cells responding to viral infection, there was a profound alteration of the 
displayed self-peptides, 40% of which were derived from interferon-stimulated genes 
(ISG) 106. If such potent effects of IFNs on antigen processing/presentation were 
occurring during T cell development, this would have significant implications for the 
establishment of T cell tolerance. We made the discovery that IFN-I and IFN-III are 
constitutively produced in the thymus and activate all the major thymic APCs. The 
details of this study are presented in chapter 3 of this dissertation.  
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Chapter 2 The lineage stability and 
suppressive program of regulatory T cells 




Regulatory T (Treg) cells are distinct T lymphocytes that control immunological 
self-tolerance and homeostasis 12,13. The lineage-defining transcription factor Forkhead 
box P3 (FOXP3), together with other transcription regulators, induces Treg-cell 
development in the thymus. T-cell receptor (TCR)- and interleukin-2 receptor (IL-2R)-
derived instructive signals act in two steps to induce the Foxp3 gene expression in 
developing Treg cells 107–109. Deleting or mutating the Foxp3 gene leads to the scurfy 
phenotype characterized by multi-organ inflammation in mice 110–112. In mature Treg 
cells, continued expression of FOXP3 maintains their lineage identity 113,114; however, a 
small but significant population of Treg cells may lose FOXP3 expression and acquire 
effector T-cell activities in normal and particularly inflammatory settings 115–117. 
Nevertheless, molecular mechanisms controlling FOXP3 protein stability under 
homeostatic and pathologic conditions are not well understood. 
Effector Treg (eTreg) cells are the most biologically potent population of Treg 
cells 42,118. Recent studies have demonstrated that pathways that regulate Treg-cell 
development are also required for the formation and function of eTreg cells. 
Continuous TCR signaling maintains the transcriptional program and suppressive 
function of eTreg cells, without affecting Foxp3 gene expression 119,120. IL-2R and 
downstream STAT5 signaling are also indispensable for eTreg-cell differentiation and 
function by controlling a distinct set of genes that are separable from those regulated 
by TCR signaling 121. It is still unclear how Treg cells integrate these pathways to 
maintain the suppressive program. 
Post-translational modification networks exist in Treg cells to rapidly integrate 
signals from diverse environmental stimuli to modulate Treg-cell function accordingly. 
In this regard, FOXP3 protein has been intensively investigated. FOXP3 can be 
regulated by phosphorylation, acetylation, and ubiquitination in response to 
environmental changes to modulate its protein stability and DNA-binding ability 59. In 
recent years, a novel modification was discovered: O-linked N-Acetylglucosamine (O-
GlcNAc) modifies intracellular proteins at serine or threonine residues 122. O-
GlcNAcylation is radically different from other types of glycosylation, and analogous to 
phosphorylation plays a central role in signaling pathways relevant to chronic human 
diseases including cardiovascular disease, diabetes, neurodegeneration, and cancer 
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60,123. The enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) mediate 
the addition and removal of O-GlcNAc, respectively. We and others have demonstrated 
that O-GlcNAc signaling acts as a hormone and nutrient sensor to control many 
biological processes such as gene transcription, protein stability, and cell signaling 124–
127.  
Earlier studies have shown that T cells express and upregulate O-
GlcNAcylation upon immune activation 128. T cell-specific ablation of OGT resulted in 
an increase of apoptotic T cells 129, and blocked T cell progenitor renewal, malignant 
transformation and peripheral T cell clonal expansion 130. These data demonstrate that 
protein O-GlcNAcylation links TCR signaling to T cell differentiation and function; 
however, the role of O-GlcNAcylation in Treg cells has not been studied. 
Here, we demonstrate that protein O-GlcNAcylation is abundant, and is 
functionally important in Treg cells by modifying FOXP3 and STAT5. Selective ablation 
of OGT in Treg cells leads to an aggressive autoimmune syndrome in mice as a result 
of Treg lineage instability and eTreg cell deficiency. On the other hand, 
pharmacological elevation of protein O-GlcNAcylation enhances the suppressive 
activity of human Treg cells, which will provide insights to help us better manipulate 
these cells in patients to treat diseases such as autoimmune disorders, transplant 




2.2.1 FOXP3 is modified and stabilized by O-GlcNAcylation 
TCR-activated protein O-GlcNAcylation is critical for T-cell development and 
function 130. We found that similar to CD4+CD25- naïve T cells, CD4+CD25+FOXP3+ 
Treg cells displayed abundant expression of OGT and global protein O-GlcNAcylation 
(Fig. 2.1A and B), implying a potential role of O-GlcNAcylation in Treg cells. Consistent 
with findings in T cells, TCR activation further promoted protein O-GlcNAcylation in 
Treg cells ex vivo (Fig. 2.1C). We also stimulated naïve T cells with TGFβ to generate 
induced Treg (iTreg) cells in vitro. Compared with cells only treated with anti-
CD3/CD28 beads, iTreg cell showed increased levels of the Ogt gene expression and 
global protein O-GlcNAcylation (Fig. 2.2A and B). These data indicate that TCR 
activates protein O-GlcNAcylation in Treg cells. 
The FOXP3 protein is subjected to various posttranslational modifications that 
are required for lineage maintenance and suppressive function 59. Thus, we sought to 
test whether the FOXP3 protein itself could be modified by O-GlcNAcylation. FOXP3 
O-GlcNAcylation could be detected when ectopically expressed in human embryonic 
kidney (HEK) 293 cells (Fig. 2.1.D). OGT overexpression increased levels of total and 
O-GlcNAcylated FOXP3, while OGA decreased FOXP3 protein expression and its O-
GlcNAcylation (Fig. 2.1D). Similarly, levels of total and O-GlcNAcylated FOXP3 were 
increased when OGA was inhibited by Thiamet-G (TMG); in contrast, inhibition of OGT 
by ST045849 decreased both total and O-GlcNAcylated FOXP3 (Fig. 2.1E). FOXP3 
protein degradation induced by the protein synthesis inhibitor cycloheximide (CHX) 
could be prevented by the proteasome inhibitor MG132 (Fig. 2.1F), indicating that 
FOXP3 was degraded through a ubiquitin/proteasome-dependent pathway. OGT 
overexpression or OGA inhibition increased FOXP3 stability (Fig. 2.1F-H), while OGA 
overexpression or OGT inhibition destabilized FOXP3 (Fig. 2.1G and I). The ubiquitin 
ligase STUB1 and the deubiquitinase USP7 have been reported to control FOXP3 
polyubiquitination and degradation 131,132. STUB1 overexpression reduced FOXP3 
levels, which could not be further decreased by OGA. When USP7 was present, OGT 
could not further increase FOXP3 protein levels (Fig. 2.2C). These data suggest that 
O-GlcNAcylation may counteract ubiquitination to stabilize FOXP3 protein. 
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Figure 2.1. O-GlcNAc-cycling enzymes regulate FOXP3 stability in vitro. 
(A, B) Mean fluorescence intensity (MFI) of OGT (A) and O-GlcNAcylation (B) in CD4+CD25- 
naïve T cells, CD4+CD25+FOXP3+ Treg cells and corresponding Fluorescence Minus One 
(FMO) negative controls. (C) Treg cells isolated from wildtype mice were stimulated with or 
without anti-CD3/CD28 beads for 24h ex vivo (n = 3). MFI of FOXP3 and O-GlcNAcylation was 
analyzed in CD4+CD25+ FOXP3+ Treg cells. (D, E) HEK 293 cells were transfected FOXP3 
together with OGT or OGA (D) or treated with inhibitors of OGT (ST045849) or OGA (TMG) (E). 
FOXP3 O-GlcNAcylation was determined by immunoprecipitation followed by western blotting. 
(F) FOXP3 stability was determined by treatment of cycloheximide (CHX) in combination with 
MG132, DMSO was used as a control. (G-I) FOXP3 stability was determined in the presence of 
OGT/OGA overexpression (G), TMG (H), or ST045849 (I). Data are shown as mean ± s.e.m. * 
p<0.05 by unpaired student’s t-test. 
 
 
Figure 2.2. iTreg cells showed increased levels of the Ogt gene expression and global 
protein O-GlcNAcylation. 
(A, B) CD4+CD25- cells isolated from the LNs and spleen of wildtype mice were activated for 5-
day with anti-CD3/CD28 beads in the presence of TGF-β to generate iTreg cells ex vivo. mRNA 
levels of Ogt (A, n = 3) and global protein O-GlcNAcylation (B) were measured. (C) Expression 
of FOXP3 protein in HEK 293 cells co-transfected with OGT or OGA and STUB1 or USP7. Data 
are shown as mean ± s.e.m. *p<0.05 by unpaired student’s t-test. 
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We then sought to determine whether O-GlcNAcylation controls FOXP3 protein 
stability in Treg cells. CD4+CD25+ Treg cells from inducible OGT knockout (KO) mice 
(Ubc-Cre/ERT2+Ogtfl/Y) were isolated and expanded ex vivo in the presence of anti-
CD3/CD28 antibodies and recombinant IL-2. 4-Hydroxytamoxifen (4-OHT) treatment in 
wildtype cells had no adverse effect on protein O-GlcNAcylation, FOXP3 expression, or 
Treg-cell number (Fig. 2.3A-C). In Ubc-Cre/ERT2+Ogtfl/Y cells, however, 4-OHT 
reduced global O-GlcNAcylation (Fig. 2.3D), FOXP3 protein abundance on a per-cell 
basis (Fig. 2.4A and B), and frequencies of CD4+CD25+ (Fig. 2.3E) and CD4+FOXP3+ 
Treg cells (Fig. 2.4C and D), demonstrating that loss of O-GlcNAcylation destabilizes 
FOXP3 protein in Treg cells ex vivo.  
  
Figure 2.3. 4-Hydroxytamoxifen (4-OHT) treatment had no adverse effects in wildtype 
cells. 
(A-C) Isolated Treg cells from Ubc-CreER-Ogtfl/Y mice were treated for 3-day 4-OHT ex vivo. 
Ethanol was used as a control. MFI of O-GlcNAcylation (A) and FOXP3 (B) among 
CD4+FOXP3+ Treg cells. Frequencies of CD4+FOXP3+ Treg cells were shown in (C). (D) MFI of 
O-GlcNAcylation in CD4+FOXP3+ Treg cells from Ubc-CreER+Ogtfl/Y mice that were treated with 
ethanol or 4-OHT, n = 4. (E) Representative flow cytometry and quantification of the frequencies 
of CD4+CD25+ Treg cells from Ubc-CreER+Ogtfl/Y mice that were treated with ethanol or 4-OHT, 
n = 4. (F) Forkhead responsive element (FHRE)-luciferase assay in HEK 293 cells transfected 
with FOXP3 or FOXP3-5A in the presence/absence of OGT. pIS1-Rluc was co-transfected to 
control transfection efficiency. OGT-induced activation of FOXP3 suppressive activity on FHRE 




To identify sites of FOXP3 O-GlcNAcylation, Flag-tagged FOXP3 was 
expressed in HEK 293 cells together with OGT, immunopurified with anti-Flag beads, 
trypsin digested, and analyzed by liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) using electron transfer dissociation (ETD). Multiple O-
GlcNAcylation sites were identified. Mutating 5 of these sites, including Thr38, Ser57, 
Ser58, Ser270, and Ser273, to alanine (5A) on the FOXP3 protein significantly blunted 
its O-GlcNAcylation level (Fig. 2.4E), reduced its stability (Fig. 2.4F), and ablated its 
transcriptional suppression activity induced by OGT (Fig. 2.3F). We then retrovirally 
transduced FOXP3 and FOXP3-5A into CD4+CD25- conventional T cells and flow 
cytometric analyses of transduced cells showed that the protein expression level of 
FOXP3-5A was much lower than that of wildtype FOXP3 (Fig. 2.4G and H). These 
results indicate that O-GlcNAcylation is required to stabilize FOXP3. 
  
Figure 2.4. O-GlcNAcylation stabilizes the FOXP3 protein in Treg cells. 
(A-D) Treg cells isolated from Ubc-CreER+Ogtfl/Y mice were treated with 4-OHT for 3-day ex 
vivo, ethanol was used as the control, n = 4 each group. MFI of FOXP3 in CD4+FOXP3+ Treg 
cells was analyzed in (A) and quantified in (B). Representative flow cytometry of CD4+ 
FOXP3+Treg cells was plotted in (C) and the frequencies of Treg cells were shown in (D). (E) 
FOXP3 or FOXP3-5A were transfected in HEK 293 cells with or without OGT. FOXP3 O-
GlcNAcylation was determined by immunoprecipitation followed by Western blotting. (F) FOXP3 
and FOXP3-5A stability was determined in the presence of OGT overexpression. (G, H) 
CD4+CD25- naïve T cells isolated from wildtype mice were infected with retroviruses expressing 
FOXP3 or FOXP3-5A in the presence of anti-CD3/CD28 beads (n = 4). MFI of FOXP3 was 
analyzed (G) and quantified (H) in CD4+FOXP3+ Treg cells. Data are shown as mean ± s.e.m. 
*p<0.05; **p<0.01 by unpaired student’s t-test (B, D) and paired student’s t-test (H). 
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2.2.2 OGT-deficiency in Treg cells leads to a scurfy phenotype 
To directly examine whether OGT regulates mature Treg cell function in vivo, 
we generated mice with Treg cell-specific deletion of OGT by using Cre recombinase 
driven by the endogenous Foxp3 locus (Foxp3YFP-Cre) to delete the loxP-flanked Ogt 
gene after FOXP3 was expressed in Treg cells. Of note, the Foxp3 and Ogt genes are 
located about 40 centimorgans apart on the X Chromosome; thus, we were able to 
successfully obtain KO mice. Protein O-GlcNAcylation was specifically diminished in 
Treg cells but not non-Treg CD4+ T, CD8+ T, B, or natural killer cells (Fig. 2.5A). 
Compared to Foxp3YFP-Cre/YOgtwt/Y control mice, Foxp3YFP-Cre/YOgtfl/Y male KO mice 
progressively developed systemic autoimmune lesions including conjunctivitis, 
dermatitis, hunched posture (Fig. 2.6A), extensive lymphadenopathy and 
splenomegaly (Fig. 2.6B), and loss of body weight (Fig. 2.6C). KO male mice became 
moribund at approximately 4 weeks of age (Fig. 2.6D), and massive lymphocytic 
infiltration could be seen in colon epithelium, skin epidermis, liver sinusoids, and lung 
interstitium (Fig. 2.6E). 
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Figure 2.5. Protein O-GlcNAcylation deficiency and effects were specific to Treg cells. 
(A) MFI of O-GlcNAcylation in indicated cell populations from Foxp3YFP-Cre/Y Ogtwt/Y and 
Foxp3YFP-Cre/Y Ogtfl/Y mice. (B) Total number of CD4+ and CD8+ T cells in the LNs from 2-week-
old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, n = 4 each group. (C) Representative 
flow cytometry plot and quantification of the frequencies showing CD19+B220+ B cells among 
single cells in the LNs of 2-week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, n = 5 
each group, n = 5. (D) Levels of IgA, IgG1, IgG2a, IgG2b, IgG3, IgM, Kappa and lamda in sera of 
Foxp3YFP-Cre/Y Ogtwt/Y (n = 5) and Foxp3YFP-Cre/Y Ogtfl/Y (n = 7) mice. (E-G) Total numbers of T-
BET+ (E), GATA-3+ (F) and RORγT+ (G) cells among CD4+ T cells in the LNs from 2-week-old 
Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, n=4 each group.  (H, I) Frequencies of IL-5+ 
(H) and IL-13+ (I) cells in CD4+FOXP3- T cells stimulated with PMA/lonomycin in the LNs of 2-
week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, n = 5. Data are shown as mean ± 
s.e.m. *p<0.05; **p<0.01; ***p<0.001 by unpaired student’s t-test. 
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We then analyzed the lymphocyte compartment at the age of 2 weeks, before 
an autoimmune phenotype was overtly apparent. The absolute numbers of CD4+ and 
CD8+ T cells were increased in the lymph nodes (LNs) of Foxp3YFP-Cre/Y Ogtfl/Y mice (Fig. 
2.5B). The percentage of effector/memory cells (CD44hiCD62Llo) within the CD4+ and 
CD8+ compartments were consistently higher in both the LNs and the spleen of 
Foxp3YFP-Cre/Y Ogtfl/Y KO mice than those in Foxp3YFP-Cre/Y Ogtwt/Y controls (Fig. 2.6F, G). 
B cell frequency in the LNs and levels of IgG, IgM, and free kappa and lambda chains 
in the serum were upregulated in KO mice (Fig. 2.5C and D). Moreover, the 
frequencies and absolute numbers of effector CD4+ subsets including T helper (Th) 1, 
Th2, and Th17 were all increased (Fig. 2.6H-K and Fig. 2.5E-G). However, we could 
only observe significantly increased expression of interferon-γ (IFNγ) in CD4+FOXP3- T 
cells in Foxp3YFP-Cre/Y Ogtfl/Y KO mice (Fig. 2.6L). Expression of IL-4, IL-5, IL-13, and IL-
17 remained unchanged (Fig. 2.6L and Fig. 2.5H, I).  These observations reveal an 
excessive Th1-dominant inflammatory response in Foxp3YFP-Cre/Y Ogtfl/Y mice.  
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Figure 2.6. OGT-deficiency in Treg cells leads to a scurfy phenotype in mice. 
(A, B) Representative images of 4-week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice 
(A) and peripheral LNs and spleen (B).  (C, D) Body weight curve (C, n = 5) and survival curve 
(D, n = 6) of Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice. (E) Representative images of 
H&E staining of the colon, skin, liver, and lung from 4-week-old Foxp3YFP-Cre/Y Ogtwt/Y and 
Foxp3YFP-Cre/Y Ogtfl/Y mice. (F, G) Representative flow cytometry plots showing CD44hiCD62Llo 
effector T cells among CD4+ (top) and CD8+ (bottom) T cells in the LNs (F) and quantification of 
the frequencies of CD44hiCD62Llo effector T cells in the LNs and spleen of 2-week-old Foxp3YFP-
Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, at least n = 6 each group (G).  (H-K) Representative 
flow cytometry plots showing T-BET+, GATA3+ and RORγT+ cells among CD4+ T cells in the 
LNs (H) and quantification of the frequencies of T-BET+ cells (I), GATA3+ cells (J) and RORγT+ 
cells (K) in the LNs and spleen of 2-week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y 
mice were shown, n = 8 each group. (L) Frequencies of IFNγ+, IL-4+ and IL-17A+ cells in 
CD4+FOXP3- T cells stimulated with PMA/lonomycin in the LNs of 2-week-old Foxp3YFP-Cre/Y 
Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, at least n = 3 each group. Data are shown as mean ± 
s.e.m. *p<0.05; **p<0.01; ***p<0.001 by unpaired student’s t-test (C, G, and I-L) and Kaplan-
Meier Analysis (D). 
2.2.3 O-GlcNAcylation stabilizes the Treg-cell lineage 
We then sought to characterize Treg cells directly. 2-week-old mice showed no 
difference in the Treg-cell frequency among CD4+TCRβ+ cells in the LNs or spleen (Fig. 
2.7A and B). The absolute number of Treg cells in the LNs of Foxp3YFP-Cre/YOgtfl/Y mice 
even surpassed those in Foxp3YFP-Cre/YOgtwt/Y controls (Fig. 2.8A and B). In the thymus, 
we did not observe any reduction in the frequency or number of Treg cells (Fig. 2.8C 
and D). In addition, there was no difference in Treg-cell proliferation or apoptosis 
between Foxp3YFP-Cre/YOgtfl/Y and Foxp3YFP-Cre/YOgtwt/Y mice, shown by Ki-67 and 
Annexin V staining, respectively (Fig. 2.8E and F). These data suggest that OGT is 
dispensable for the development of thymic Treg cells.  
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Figure 2.7. Protein O-GlcNAcylation stabilizes the Treg-cell lineage. 
(A, B) Flow cytometry of YFP+CD25+ cells among CD4+ T cells in the LNs (A) and frequencies 
of YFP+CD25+ cells in the LNs and spleen from 2-week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-
Cre/Y Ogtfl/Y mice, n = 8 each group (B). (C, D) Flow cytometry of FOXP3+CD25+ cells among 
CD4+ T cells (C) and MFI of FOXP3 in FOXP3+CD25+ Treg cells (D, n = 3-4) in the LNs from 2-
week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice.  (E) MFI of FOXP3 in OGT-
sufficient and -deficient Treg cells in the LNs from Foxp3YFP-Cre/Y Ogtfl/fl mice, n = 5. (F) 
Histogram of FOXP3 expression in CD4+CD25+YFP+ Treg cells in the LNs from 2-week-old 
Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, n = 6 each group. (G) Flow cytometry and 
quantification of the frequencies of Td-tomato+GITR+FOXP3- ex-Treg cells among CD4+ T cells 
in the LNs from Foxp3eGFP-Cre-ERT2/Y Ogtwt/Y Rosa26tdTomato/wt and Foxp3 eGFP-Cre-ERT2/Y Ogtfl/Y 
Rosa26tdTomato/wt mice, n = 4. (H, I) T-BET+, GATA3+ and RORγT+ cells among ex-Treg cells in 
the LNs from Foxp3eGFP-Cre-ERT2/Y Ogtwt/Y Rosa26tdTomato/wt and Foxp3 eGFP-Cre-ERT2/Y Ogtfl/Y 
Rosa26tdTomato/wt mice, n= 3-4. Data are shown as mean ± s.e.m. *p<0.05; **p<0.01; ***p<0.001 




Figure 2.8. Foxp3YFP-Cre/YOgtfl/Y characterization in 2-week-old mice and in the thymus. 
(A, B) Total numbers of YFP+CD25+ (A) and FOXP3+CD25+ (B) Treg cells among CD4+ T cells 
in the LNs from 2-week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, n = 4 each 
group. (C, D) Frequency (C) and total number (D) of YFP+CD25+ Treg cells among CD4+ T cells 
in the thymus from 2-week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, n = 4 each 
group. (E, F) MFI of Ki-67 (E) and Annexin V (F) among YFP+CD25+ Treg cells in the LNs from 
2-week-old Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice. (G) FOXP3 stability in Treg cells 
isolated from Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice was determined by CHX 
treatment. (H) Frequencies of YFP+ Treg cells in the LNs from Foxp3YFP-Cre/wt Ogtwt/fl and 
Foxp3YFP-Cre/wt Ogtfl/fl female mice. Data are shown as mean ± s.e.m. *, p<0.05; **, p<0.01 by 
unpaired student’s t-test. 
 
Similar to findings in induced Ubc-Cre/ERT2+Ogtfl/Y cells ex vivo (see Fig. 2.4A-
D), Treg cells from 2-week-old Foxp3YFP-Cre/YOgtfl/Y KO mice had less FOXP3 protein 
expression than those from control mice (Fig. 2.7C and D). Treating isolated Treg cells 
from Foxp3YFP-Cre/YOgtwt/Y and Foxp3YFP-Cre/YOgtfl/Y mice with CHX, we were able to find 
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decreased FOXP3 protein stability in OGT-deficient Treg cells (Fig. 2.8G). In adult 
Foxp3YFP-Cre/wtOgtfl/fl female mice, in which OGT-sufficient (YFP-) and OGT-deficient 
(YFP+) Treg cells co-existed because of random inactivation of the X chromosome, 
YFP+ OGT-deficient Treg cells displayed similar abundance as those YFP+ OGT-
sufficient Treg cells in Foxp3YFP-Cre/wtOgtwt/fl females (Fig. 2.8H). In Foxp3YFP-Cre/wtOgtfl/fl 
females, FOXP3 expression was lower in OGT-deficient Treg cells than in OGT-
sufficient Treg cells (Fig. 2.7E). These data demonstrate that OGT is required for 
FOXP3 protein stability in Treg cells. 
Continuous expression of FOXP3 maintains the Treg-cell identity. In Foxp3YFP-
Cre/YOgtfl/Y KO mice, a significant proportion of YFP+CD25+ cells lost FOXP3 expression 
when compared to their Foxp3YFP-Cre/YOgtwt/Y counterparts (Fig. 2.7F), suggesting that 
OGT-deficient cells tend to become the so-called “ex-Treg” cells or “latent” Treg cells 
116. To directly trace the Foxp3 lineage, we crossed inducible Foxp3eGFP-Cre-ERT2/YOgtfl/Y 
mice to the Rosa26tdTomato Cre-reporter line, in which a loxP-flanked STOP cassette 
preventing transcription of the tdTomato protein was inserted into the Rosa26 locus 133. 
Tamoxifen-containing diet feeding induced Treg cell-specific ablation of protein O-
GlcNAcylation (Fig. 2.9A) and progressive systemic inflammation in Foxp3 eGFP-Cre-ERT2/Y 
Ogtfl/Y Rosa26tdTomato/wt mice (Fig. 2.9B-E). Gating on the CD4+GITR+tdTomato+ 
population, we found that more FOXP3-tdTomato+ ex-Treg cells emerged in Foxp3 eGFP-
Cre-ERT2/YOgtfl/Y Rosa26tdTomato/wt KO mice than in Foxp3 eGFP-Cre-ERT2/Y Ogtwt/Y 
Rosa26tdTomato/wt controls (Fig. 2.7G). These ex-Treg cells were prone to express the 
Th1 transcription factor T-BET and the Th2 transcription factor GATA3, but not the 
Th17 transcription factor RORγT (Fig. 2.7H and I). These results show that OGT-




Figure 2.9. Tamoxifen-containing diet feeding induced Treg cell-specific ablation of 
protein O-GlcNAcylation. 
(A) MFI of O-GlcNAcylation in indicated cell populations from Foxp3eGFP-Cre-ERT2/Y Ogtwt/Y 
Rosa26tdTomato/wt and Foxp3 eGFP-Cre-ERT2/Y Ogtfl/Y Rosa26tdTomato/wt mice. (B) Representative images 
of 6-week-old Foxp3eGFP-Cre-ERT2/Y Ogtwt/Y Rosa26tdTomato/wt and Foxp3 eGFP-Cre-ERT2/Y Ogtfl/Y 
Rosa26tdTomato/wt mice fed tamoxifen food for 3 weeks and peripheral LNs and spleen. (C-E) T-
BET+ FOXP3- cells (C), GATA3+ FOXP3- cells (D) and RORγT+ FOXP3- cells (E) among CD4+ T 
cells in LNs from Foxp3eGFP-Cre-ERT2/Y Ogtwt/Y Rosa26tdTomato/wt and Foxp3 eGFP-Cre-ERT2/Y Ogtfl/Y 
Rosa26tdTomato/wt mice, n = 3-4. Data are shown as mean ± s.e.m. Data are shown as mean ± 
s.e.m. *p<0.05; ***p<0.001 by unpaired student’s t-test. 
 
2.2.4 O-GlcNAcylation is indispensable for the development of effector 
Treg cells 
In mature Treg cells, IL-2 and TCR signaling are not only required for lineage 
stability, but also for suppressive function, partially via the AKT-mTOR axis 134. The 
intensity of S6 phosphorylation but not AKT S473 phosphorylation was decreased in 
OGT-deficient Treg cells (Fig. 2.10A), suggesting a mTORC1-specific defect. In 
Foxp3YFP-Cre/Y Ogtfl/Y mice, we found that the abundance of CD44hiCD62Llo effector Treg 
(eTreg) cells was significantly lower than Foxp3YFP-Cre/Y Ogtwt/Y counterparts (Fig. 
2.11A). Strikingly, eTreg cells that express signature effector molecules such as 
KLRG1 135, PD-1 136, and CD73 137 were almost eliminated in Foxp3YFP-Cre/Y Ogtfl/Y mice 
(Fig. 2.11B-D).  
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Figure 2.10. Treg characterization in Foxp3YFP-Cre/wt Ogtfl/fl female mice. 
(A) MFI of pS6 and pS473-AKT among CD4+FOXP3+ Treg cells in LNs of 2-week-old Foxp3YFP-
Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, n = 2.  (B, C) Body weight (B, n = 12) and 
representative images of peripheral LNs, spleen and thymus (C) of Foxp3YFP-Cre/wtOgtwt/fl and 
Foxp3YFP-Cre/wtOgtfl/fl female mice.  (D-H) Frequencies of indicated cell populations among YFP+ 
Treg cells in the LNs and spleen from Foxp3YFP-Cre/wt Ogtwt/fl and Foxp3YFP-Cre/wt Ogtfl/fl female 
mice, n = 3 each group. Data are shown as mean ± s.e.m. *p<0.05; **p<0.01; ***p<0.001 by 
unpaired student’s t-test. 
 
Foxp3YFP-Cre/wt Ogtfl/fl female mice were devoid of autoimmune defects (Fig. 
2.10B and C), since they possessed both OGT-sufficient (YFP-) and OGT-deficient 
(YFP+) Treg cells because of random inactivation of the X chromosome. Nevertheless, 
we could observe significant reductions in the abundance of CD44hiCD62Llo, KLRG1+, 
PD-1+, CD73+, and CD103+ eTreg cells when comparing YFP+ OGT-deficient to YFP- 
OGT-sufficient cells in the same Foxp3YFP-Cre/wtOgtfl/fl mice (Fig. 2.11E-I). Similar 
reductions in eTreg signature molecules could be observed when comparing YFP+ 
Treg cells between Foxp3YFP-Cre/wtOgtfl/fl and Foxp3YFP-Cre/wtOgtwt/fl mice (Fig. 2.10.D-H). 




Figure 2.11. O-GlcNAcylation is required for the effector differentiation of Treg cells. 
(A, D) Frequencies of CD44hiCD62Llo (A), CD44+KLRG1+ (B), CD44+PD-1+ (C), and 
CD44+CD73+ (D) cells among YFP+CD25+ Treg cells in the LNs and spleen from 2-week-old 
Foxp3YFP-Cre/Y Ogtwt/Y and Foxp3YFP-Cre/Y Ogtfl/Y mice, at least n = 4 each group. (E-I) Frequencies 
of indicated cell populations among YFP- OGT-sufficient and YFP+ OGT-deficient 
CD4+TCRβ+CD25+GITR+ Treg cells in the LNs and spleen from Foxp3YFP-Cre/wt Ogtfl/fl mice, n = 3 
each group. Data are shown as mean ± s.e.m. *p<0.05; p<0.01; ***p<0.001 by unpaired 
student’s t-test. 
 
2.2.5 Attenuated IL-2/STAT5 signaling in OGT-deficient Treg cells 
It seemed unlikely to us that the mild downregulation of FOXP3 protein stability 
could account for the absence of eTreg-cell formation, as FOXP3 binds to the same set 
of regulatory elements in both resting Treg cells and eTreg cells 138. To gain 
comprehensive insight into the OGT-dependent transcriptional program in Treg cells, 
we performed RNA-sequencing of isolated YFP+ Treg cells from Foxp3YFP-Cre/wtOgtwt/fl 
and healthy Foxp3YFP-Cre/wtOgtfl/fl females to avoid secondary changes in gene 
expression caused by inflammation. We were able to identify 269 differentially 
expressed genes including 154 downregulated and 115 upregulated with p values less 
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than 0.01 (Fig. 2.12A). eTreg-cell markers such as klrg1, S100a4, Gzmb, and Ccr2 
were downregulated by the loss of O-GlcNAcylation (Fig. 2.12A). The transcription 
factor B lymphocyte-induced maturation protein (BLIMP)-1 is common to all eTreg cells 
139, and we found that BLIMP-1-upregulated genes were enriched in OGT-sufficient 
Treg cells, while BLIMP-1-downregulated genes were enriched in OGT-deficient Treg 
cells (Fig. 2.12B and C), suggesting that OGT maintains a transcriptional program 
similar to that of BLIMP-1+ eTreg cells. Ingenuity Pathway Analysis (IPA) identified 9 
potential upstream regulators which were all predicted to be inhibited, and the top one 
was IL-2 (Fig. 2.12D). To evaluate the responsiveness of Treg cells to IL-2, we treated 
mice with immune complexes consisting of mouse IL-2 and anti-IL-2 antibody to 
expand eTreg cells (Fig. 2.13A) 135,140. IL-2 immune complex treatment moderately 
enlarged the LNs and spleen but did not change total protein O-GlcNAcylation in Treg 
cells (Fig. 2.13B, C), suggesting IL-2 does not directly regulate O-GlcNAc signaling. 
However, protein O-GlcNAcylation was required for IL-2-stimulated development of 
eTreg cells, as the expansion of KLRG1+, GZMB+, and BLIMP-1+ eTreg populations 
was absent in OGT-deficient Treg cells (Fig. 2.12E-J and Fig. 2.13D). The increase in 
the expression of CD25 and IL-10 induced by IL-2 in OGT-sufficient cells was also 
inhibited when OGT was deleted (Fig. 2.13E and F). 
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Figure 2.12. Attenuated IL-2/STAT5 signaling in OGT-deficient Treg cells. 
(A) Hierarchical clustering of top differentially expressed genes (60 genes with FDR q values 
less than 0.1) between OGT-sufficient and -deficient Treg cells using Morpheus. (B, C) 
Enrichment plots for up- (B) and down-regulated (C) genes in Blimp1+ eTreg cells from the 
Gene Set Enrichment Analysis (GSEA) of differentially expressed genes between OGT-
sufficient and -deficient Treg cells. (D) Ingenuity Pathway Analysis (IPA) of predicted upstream 
regulators for observed changes in gene expression. (E-J) Foxp3YFP-Cre/wt Ogffl/fl female mice 
were injected with PBS or the IL-2 immune complex (n = 2-5) for 3 consecutive days. Flow 
cytometry of CD44+KLRG1+(E), CD4+GZMB+ (F) and CD4+BLIMP-1+ (G) Treg cells among YFP- 
OGT-sufficient and YFP+ OGT-deficient Treg cells (CD4+CD25+GITR+) in LNs and spleen and 
corresponding frequencies in (H-J). (K) Expression of STAT5-target genes in OGT-sufficient 
and -deficient Treg cells. (L-M) mRNA levels of Socs1 (L) and Socs3 (M) in OGT-sufficient Treg 
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cells after retrovirus infection as indicated, n = 3 each group. Data are shown as mean ± s.e.m. 




Figure 2.13. Treatment with IL-2 in Foxp3YFP-Cre/wt Ogffl/fl female mice. 
Foxp3YFP-Cre/wt Ogffl/fl female mice were injected with PBS or the IL-2 immune complex for 3 
consecutive days (A) Peripheral LNs and Spleen.  (B) MFI of O-GlcNAcylation among YFP-
OGT-sufficient or YFP+OGT-deficient Treg cells (CD4+CD25+GITR+). (C, D) MFI of CD25 (C) 
and IL10 (D) among YFP-OGT-sufficient or YFP+OGT-deficient Treg cells (CD4+CD25+GITR+), 
n = 2-5. Data are shown as mean ± s.e.m.  **p<0.01; ***p<0.001 by unpaired student’s t-test. 
 
STAT5, acting downstream of IL-2, is indispensable for the formation of KLRG1+ 
terminally differentiated Treg cells and their suppressive function 121,135. O-
GlcNAcylation of STAT5 has been shown to promote its oligomerization and 
transcriptional activity in cooperation with tyrosine phosphorylation in neoplastic cells 
141. Consistent with the defective IL-2 response, many STAT5-target genes were 
downregulated in OGT-deficient Treg cells (Fig. 2.12K). However, the IL-2-activated 
tyrosine phosphorylation of STAT5 (pY-STAT5) in Treg cells was not affected by the 
loss of OGT (Fig. 2.14A and B), again supporting the notion that O-GlcNAcylation can 
act independently of tyrosine phosphorylation 141. O-GlcNAcylation seemed not to 
regulate the cellular localization of STAT5 either (Fig. 2.14C). Retroviral expression of 
a constitutively active STAT5A (cS5) in Treg cells increased the expression of the 
STAT5-target gene Socs1 and Socs3, whereas the O-GlcNAc-deficient cS5-T92A 
diminished such effect 141 (Fig. 2.12L, M). Moreover, in OGT-deficient Treg cells, 
reconstitution of cS5 but not cS5-T92A increased Socs1 expression (Fig. 2.14D), 
suggesting that STAT5 O-GlcNAcylation is important for its transcriptional activity. 
Collectively, these data demonstrate that the deficiency in protein O-GlcNAcylation 
results in attenuated IL-2/STAT5 activity in Treg cells. 
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Figure 2.14. IL-2-activated tyrosine phosphorylation of STAT5 (pY-STAT5) in Treg cells 
was not affected by the loss of OGT. 
(A, B) MFI of O-GlcNAcylation and pY-STAT5 among YFP+CD25+ Treg cells in the LNs from 
Foxp3YFP-Cre/wt Ogtwt/fl and Foxp3YFP-Cre/wt Ogtfl/fl female mice (A) and Foxp3YFP-Cre/Y Ogtwt/Y and 
Foxp3YFP-Cre/Y Ogtfl/Y male mice (B) stimulated with IL-2 in vitro, PBS incubation was used as 
control. (C) Representative images of STAT5 nuclear translocation in HEK 293 cells transfected 
with cS5 or cS5-T92A. (D) mRNA levels of Socs1 in OGT-deficient Treg cells after retrovirus 
infection as indicated, n = 3. Data are shown as mean ± s.e.m. *, p<0.05 by one-way ANOVA. 
 
2.2.6 Constitutive activation of STAT5 partially rescues Treg-cell 
dysfunction 
 Treg cell-specific deletion of OGT resulted in a scurfy phenotype with 
comparable early onset and disease severity to those observed upon IL-2R or STAT5 
ablation 121. Expression of a constitutively active form of STAT5B-CA partially rescues 
IL-2R deficient Treg function 121. We next sought to determine whether STAT5 
activation could restore Treg cell function in Foxp3YFP-Cre/Y Ogtfl/Y mice by crossing them 
to a Cre-inducible line overexpressing STAT5B-CA at the Rosa26 locus (Rosa26Stat5b-
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CA) 121. Remarkably, the Foxp3YFP-Cre/YOgtfl/YRosa26Stat5b-CA/wt mice with STAT5B-CA 
overexpression specifically in OGT-deficient Treg cells alleviated skin inflammation 
(Fig. 2.15A), reduced size of the LNs and spleen (Fig. 2.15B), and prolonged lifespan 
(Fig. 2.15C), when compared to Foxp3YFP-Cre/YOgtfl/Y mice. Consistent with the role of 
STAT5 in regulating Foxp3 transcription and Treg-cell development 107,121,142, FOXP3 
protein expression was restored to a level comparable to wildtype mice and the 
frequency of Treg cells was further increased when STAT5B-CA was present (Fig. 
2.15D, E, and Fig. 2.16A). Meanwhile, the eTreg cell population was significantly 
boosted to a level comparable to wildtype mice, shown as CD44hiCD62Llo (Fig. 2.15F 
and Fig. 2.16B) and CD44+KLRG1+ subsets (Fig. 2.15G and Fig. 2.16C). However, the 
expression levels of CD73 and PD-1 on a per-cell basis did not change (Fig. 2.16D), 
suggesting a partial rescue in the suppressive function of Treg cells by STAT5B-CA. 
Moreover, the fraction of YFP+ OGT-deficient Treg cells that lost FOXP3 expression as 
a result of protein instability was substantially inhibited by the presence of STAT5B-CA 
(Fig. 2.15H and Fig. 2.16E), indicating that STAT5B-CA also restored Treg lineage 
stability. 
Accordingly, STAT5B-CA overexpression reduced the number of total CD4+ 
and CD8+ T cells (Fig. 2.15I and J) and the frequency of memory/effector CD4+ and 
CD8+ T cells in Foxp3YFP-Cre/YOgtfl/YRosa26Stat5b-CA/wt mice (Fig. 2.15K, L, and Fig. 
2.16F). In addition, STAT5B-CA overexpression prevented the increase in Th1 and 
Th2 cells caused by loss of O-GlcNAcylation in Treg cells (Fig. 2.15M-O and Fig. 
2.16G) and reduced the production of IFNγ by CD4+ and CD8+ T cells (Fig. 2.15P and 
Fig. 2.16H and I). Collectively, these data show that restoring STAT5 signaling in OGT-
deficient Treg cells improves lineage stability and suppressive function, thereby 
delaying the autoimmune responses in mice. 
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Figure 2.15. Constitutive activation of STAT5 partially rescues Treg cell dysfunction. 
(A, B) Representative images of mice (A) and peripheral LNs and spleen (B) from 2-week-old 
Foxp3YFP-Cre/Y Ogtfl/Y and Foxp3YFP-Cre/YOgtfl/Y Rosa26Stat5b-CA/wt mice.  (C) Survival curve of 
Foxp3YFP-Cre/Y Ogtfl/Y and Foxp3YFP-Cre/YOgtfl/Y Rosa26Stat5b-CA/wt mice (n = 6).  (D) MFI of FOXP3 in 
FOXP3+CD25+ Treg cells in the LNs from 2-week-old Foxp3YFP-Cre/Y Ogtwt/Y, Foxp3YFP-Cre/Y Ogtfl/Y 
and Foxp3YFP-Cre/YOgtfl/Y Rosa26Stat5b-CA/wt mice, at least n = 3 each group. (E) Frequencies of 
FOXP3+CD25+ Treg cells among CD4+ T cells, at least n = 9 each group. (F-G) Frequencies of 
CD44hiCD62Llo (F) and CD44+KLRG1+ (G) eTreg cells among FOXP3+CD25+ Treg cells in the 
LNs from 2-week-old Foxp3YFP-Cre/Y Ogtwt/Y, Foxp3YFP-Cre/Y Ogtfl/Y and Foxp3YFP-Cre/YOgtfl/Y 
Rosa26Stat5b-CA/wt mice, at least n = 6 each group. (H) Histogram of FOXP3 expression in 
CD4+CD25+YFP+ Treg cells in the LNs from 2-week-old Foxp3YFP-Cre/Y Ogtwt/Y, Foxp3YFP-Cre/Y 
Ogtfl/Y and Foxp3YFP-Cre/YOgtfl/Y Rosa26Stat5b-CA/wt mice.  (I, J) Absolute number of CD4+ (I) and 
CD8+ (J) T cells in the LNs, at least n = 3 each group. (K, L) Frequencies of CD44hiCD62Llo 
effector T cells in CD4+ (K) and CD8+ cells (L), at least n = 7 each group. (M-O) Frequencies of 
T-BET+ (M), GATA3+ (N) and RORγT+ (O) populations among CD4+FOXP3- cells in the LNs, at 
least n = 6 each group. (P) Frequencies of INFγ, IL-4 and IL-17A-producing CD4+FOXP3- cells 
from Foxp3YFP-Cre/Y Ogtfl/Y and Foxp3YFP-Cre/YOgtfl/Y Rosa26Stat5b-CA/wt mice, at least n = 3 each 
group. Data are shown as mean ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001 by Kaplan-Meier 
Analysis (C), unpaired student’s t-test (P) and one-way ANOVA (D–G, I–O).  
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Figure 2.16. Characterization of Foxp3YFP-Cre/YOgtfl/YRosa26Stat5b-CA/wt mice. 
(A) Flow cytometry of FOXP3+CD25+ Treg cells among CD4+ T cells in the LNs from Foxp3YFP-
Cre/Y Ogtwt/Y, Foxp3YFP-Cre/Y Ogtfl/Y and Foxp3YFP-Cre/YOgtfl/YRosa26Stat5b-CA/wt mice. (B, C) Flow 
cytometry of CD44hiCD62Llo eTreg cells (B) and CD44+KLRG1+ eTreg cells (C) among 
FOXP3+CD25+ Treg cells in the LNs from Foxp3YFP-Cre/Y Ogtwt/Y, Foxp3YFP-Cre/Y Ogtfl/Y and 
Foxp3YFP-Cre/YOgtfl/YRosa26Stat5b-CA/wt mice. (D) MFI of O-GlcNAcylation, CD73 and PD-1 among 
FOXP3+CD25+ Treg cells.  (E) Frequencies of FOXP3+ and FOXP3-  cells among 
CD4+CD25+YFP+ Treg cells in the LNs, at least n = 6 each group. (F) Flow cytometry of 
CD44hiCD62Llo cells among CD4+ and CD8+ T cells in the LNs. (G) Flow cytometry of T-BET+, 
GATA3+ and RORγT+ population among CD4+FOXP3- cells in the LNs. (H, I) Flow cytometry of 
IFNγ-expressing cells among CD4+FOXP3- (H) and CD8+ T cells (I) in the LNs. Data are shown 
as mean ± s.e.m. *p<0.05; **p<0.01 by one-way ANOVA. 
 
2.2.7 Activating O-GlcNAcylation promotes the suppressive program of 
Treg cells  
The therapeutic potential of Treg cells for autoimmune disorders and graft-
versus-host disease (GVHD) has been well characterized in preclinical and early 
clinical studies 143,144. We then asked whether enhancing protein O-GlcNAcylation 
could augment the suppressive function of Treg cells. We first treated mouse Treg cells 
with TMG to inhibit OGA (Fig. 2.17A), the enzyme removing O-GlcNAc moieties from 
proteins 145, and found that elevating protein O-GlcNAcylation by TMG increased the 
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level of FOXP3 protein on a per cell basis (Fig. 2.17B and C) and the number of 
CD4+FOXP3+ Treg cells (Fig. 2.18A), again demonstrating that O-GlcNAcylation 
stabilizes FOXP3 and Treg cell lineage. In addition, TMG treatment enhanced the 
expression of STAT5-target genes Socs1 and Socs3 (Fig. 2.17D, E), and the 
expression of activation markers including Klrg1, Pd-1 and, to a lesser extent, Cd73 
and Cd44 in mouse Treg cells (Fig. 2.17F).  
 
Figure 2.17. Activating O-GlcNAcylation promotes Treg-cell suppressive function. 
(A-C) MFI of protein O-GlcNAcylation (A), FOXP3 (B, C) in mouse CD4+FOXP3+ Treg cells 
treated with TMG, H2O treatment was used as a control (n = 5). (D, E) mRNA levels of 
Socs1(D) and Socs3 (E) in mouse Treg cells treated with TMG, H2O treatment was used as a 
control (n = 3). (F) Gene expression in iTreg cells treated with TMG, H2O treatment was used as 
a control (n = 2). (G, H) MFI of protein O-GlcNAcylation (G) and FOXP3 (H) in human tTreg 
cells treated with TMG for 7 days (n = 3), H2O treatment was used as a control. (I) mRNA levels 
of SOCS3 in human tTreg cells treated with TMG, H2O treatment was used as a control (n = 3). 
(J, K) Suppression activity of human tTreg cells treated with TMG for 7 days, H2O treatment 
was used as a control. Data are shown as mean ± s.e.m. *p<0.05 by unpaired student’s t-test. 
 
Finally, we purified CD4+CD25+CD127-CD45RA+ naïve human thymus Treg 
(tTreg) cells from peripheral blood mononuclear cells (PBMNCs) as previously 
described 146. OGA inhibition by TMG significantly increased intracellular O-GlcNAc 
levels (Fig. 2.17G) but had no effect on FOXP3 expression or tTreg-cell expansion 
(Fig. 2.17H and Fig. 2.18B), indicating that the endogenous O-GlcNAcylation was 
sufficient to maintain human FOXP3 stability. Nevertheless, we observed a significant 
increase in the expression of SOCS3 gene (Fig. 2.17I) and the suppressive activity of 
human Treg cells when treated with TMG (Fig. 2.17J, K, and Fig. 2.18C). Collectively, 
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these results reveal a fundamental role for O-GlcNAc signaling in supporting the 
suppressive program of mouse and human Treg cells. 
  
Figure 2.18. TMG treatment of mouse and human Tregs. 
(A) Flow cytometry and quantification of the frequencies of mouse CD4+FOXP3+ Treg cells 
treated with TMG, H2O treatment was used as a control, n = 5 each group. (B) Frequencies of 
human tTreg cells expansion treated with or without TMG for 7 days, n=3. (C) Representative 
plots showing the cell proliferation of CD8+ cells labeled with CFSE. Data are shown as mean ± 




In mature Treg cells, FOXP3 expression and signals from TCR and IL-2R are 
continuously required for Treg lineage stability and suppressive function 113,114,119–121,147. 
In this study, we have demonstrated that, in response to TCR activation, protein O-
GlcNAcylation stabilizes FOXP3 and activates STAT5, thus integrating critical signaling 
nodes for Treg-cell homeostasis and function.  
Our data suggest that O-GlcNAcylation promotes FOXP3 stability by 
counteracting with ubiquitination. Prior studies have demonstrated that 
polyubiquitination marks FOXP3 for protein degradation via the proteasome 148–150. 
Treatment of Treg cells with a pan-deubiquitinase inhibitor reduces FOXP3 protein 
levels and decreases suppressive activity 132. Ubiquitination dynamics of FOXP3 is 
dictated by the ubiquitin ligase STUB1 and the deubiquitinase USP7 131,132. We 
postulate that O-GlcNAcylation inhibits STUB1-mediated polyubiquitination and/or 
facilitates USP7-mediated deubiquitination to stabilize FOXP3.  By identifying and 
mutating O-GlcNAc sites on the FOXP3 protein, we were able to show reduced FOXP3 
stability when O-GlcNAcylation was ablated (Fig. 2.4), suggesting a potential direct 
interplay between O-GlcNAcylation and ubiquitination. Nonetheless, O-GlcNAc 
signaling can modulate proteasome activity and other posttranslational modifications to 
indirectly control FOXP3 protein abundance 127.  
Foxp3YFP-Cre/YOgtfl/Y mice developed a scurfy phenotype at a similar pace as 
observed in mice with germline Foxp3 deficiency 110–112. When OGT was absent, 
FOXP3 stability was only modestly reduced ex vivo and in vivo (Fig. 2.4 and 2.7). 
Thus, FOXP3 instability is only one of the contributors to Treg-cell dysfunction 
observed in Foxp3YFP-Cre/YOgtfl/Y mice. In Treg cells with TCR ablation, there was also a 
slight reduction in FOXP3 protein expression, without affecting Foxp3 transcription 
119,120. It would be interesting to determine whether TCR signaling controls FOXP3 
stability through protein O-GlcNAcylation.  
In conventional T (Tconv) cells, O-GlcNAcylated proteins are abundant and 
dynamically regulated by TCR activation 151–153. These proteins are involved in many 
biological processes, including TCR signaling (LCK, ZAP70, STAT3, c-JUN, NFAT, 
etc), transcriptional and translational processes, and mRNA processing. Compared to 
Tconv cells, Treg cells possess a unique proteomic signature to accommodate specific 
 43 
metabolic requirements and regulatory function 154,155. It is unclear if O-GlcNAcylated 
proteins identified in Tconv cells can be modified in Treg cells. Future O-GlcNAc 
proteomics is needed to not only profile O-GlcNAcylated proteins in response to TCR 
activation but also identify other potential targets that could regulate Treg-cell function. 
Nevertheless, it is unlikely that TCR signaling is a major pathway that mediates the 
effect of O-GlcNAcylation, as the activation of immune system in Treg-specific TCR 
deletion mice was much milder than we observed in Foxp3YFP-Cre/YOgtfl/Y mice 119,120. 
Through gene expression profiling, we predicted that the IL-2/STAT5 signaling 
pathway was inhibited in OGT-deficient Treg cells. In accordance with the prediction, 
we found that eTreg cells failed to expand in response to IL-2 immune complexes 
when OGT was ablated and the scurfy phenotype in Foxp3YFP-Cre/YOgtfl/Y mice could be 
partially ameliorated by a constitutive-active form of STAT5B. In OGT-deficient Treg 
cells, even though the expression of STAT5 target genes was significantly 
downregulated, we did not observe any change in levels of pY-STAT5, suggesting O-
GlcNAcylation can function independently of tyrosine phosphorylation. This is 
consistent with a recent study showing that O-GlcNAcylation and tyrosine 
phosphorylation act together to activate STAT5-depedent malignancies 141. Although 
O-GlcNAcylation at threonine 92 is required for strong pY-STAT5A upon IL-3 
stimulation, erythropoietin-activated pY-STAT5A and IL-2-stimulated T-cell proliferation 
were comparable between cells expressing constitutively active STAT5A (cS5) and 
cS5-T92A that lacks O-GlcNAcylation. In addition, there was no significant change in 
pY-STAT5B when introducing the T92A mutant to human STAT5B or the hyperactive 
N642H derivative 141. These findings indicate that O-GlcNAcylation and IL-2-induced 
pY-STAT5 have separate but additive effects on STAT5 function.    
In TCR-triggered naïve T cells, glucose and glutamine flux into the hexosamine 
biosynthetic pathway (HBP) to generate UDP-GlcNAc, which fuels the protein O-
GlcNAcylation 130. O-GlcNAcylation is critical for self-renewal and malignant 
transformation of T cell progenitors, thymocyte positive selection, and clonal expansion 
of peripheral T cells 130. It is still unclear how TCR-activation promotes the HBP flux. In 
addition, Treg cells and CD4+ Tconv cells program distinct cellular metabolism 156. 
Tconv cells are dependent on aerobic glycolysis and glutaminolysis to fulfill their 
bioenergetic and biosynthetic demand of proliferation 157. However, Treg cells couple 
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TCR and IL-2R signals with mTORC1-dependent lipid biosynthesis to establish their 
functional program 134. It is thus unlike that TCR-activated protein O-GlcNAcylation in 
Treg cells is a result of increased glucose flux. Recently, our findings in hepatocytes 
have indicated that Ca2+-dependent CaMKII phosphorylates and activates OGT 158. 
Ca2+ release is induced downstream of TCR signaling and the Ca2+-dependent serine-
threonine phosphatase Calcineurin, by dephosphorylating and mediating nuclear 
translocation of NFAT, is crucial for Treg cell development 159,160. It is warranted to test 
whether Ca2+ signaling mediates TCR-activated O-GlcNAcylation via modulating OGT 
activity. 
Treg cells restrain autoimmune disease, suppress inflammation, prevent organ 
transplant rejection, and contribute to immune dysfunctions in some infections and 
cancers 161,162. However, challenges for Treg cell immunotherapy exist as Treg cells 
display functional instability and heterogeneity. Our study has identified OGT and 
protein O-GlcNAcylation as a regulatory hub connecting TCR, FOXP3, and IL-2R to 
support Treg-cell lineage stability and suppressive function. More importantly, 
pharmacological elevation of O-GlcNAcylation by inhibiting OGA augments the 
suppressive activity of human Treg cells, thus targeting O-GlcNAcylation can facilitate 
the translation of Treg cell therapy into the clinic to treat diseases such as autoimmune 





Foxp3YFP-cre mice (stock number 016959) and Foxp3eGFP-Cre-ERT2 mice (stock 
number 016961) were purchased from the Jackson Laboratory. Rosa26Stat5b-CA mice 
were provided by Dr. Alexander Rudensky at Memorial Sloan Kettering Cancer Center 
121. Ogtfl/fl Mice (Jackson Laboratory stock number 004860) were kindly provided by Dr. 
Xiaoyong Yang at Yale University. Rosa26tdTomato reporter mice (Jackson Laboratory 
stock number 007909) were kindly provided by Dr. Jop van Berlo at University of 
Minnesota. UbcCreER+ mice (Jackson Laboratory stock number 007001) were kindly 
provided by Dr. Doug Mashek at University of Minnesota. All mice were on C57BL/6 
background. Foxp3YFP-Cre/Y Ogtfl/Y male mice were used at 2-week-old unless specific 
noted, with the same age Foxp3YFP-Cre/Y Ogtwt/Y as control. Other mice were used at 6-
12 weeks old unless specific noted. Mice were free to access water and fed on a 
regular chow or Tamoxifen food (Teklad, TD.130860) as indicated. All procedures were 
approved by the Institutional Animal Care and Use Committee at the University of 
Minnesota. 
For IL-2-immune complex administration, IL-2 (eBioscience, catalog no. 14-
8021-64) and JES6-1A12 (eBioscience, catalog no. 16-7022-81) were incubated at a 
molar ratio of 2 to 1 in PBS at room temperature for 30 min followed by 3 consecutive 
days i.p. injections. For female mice, each mouse received 1 μg of IL-2 and 5 μg of 
JES6-1A12 in 200ul PBS at 6-week-old. For male mice, each mouse received 0.5 μg of 
IL-2 and 2.5 μg JES6-1A12 in 100ul PBS at 2-week-old. 
For histology, mouse tissues were dissected and fixed in 10% buffered 
formalin. Sectioning and haematoxylin & eosin (H&E) staining were performed by the 
Comparative Pathology Shared Resource of UMN. 
2.4.2 Human participants 
Nonmobilized PB leukapheresis products were collected from normal adult 
volunteers with Food and Drug Administration (FDA)–approved/cleared apheresis 
instruments at Memorial Blood Center (St. Paul, MN) as previously described 146. 
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Written informed consent was obtained from all subjects with approval from the 
University of Minnesota Institutional Review Board. 
2.4.3 Naïve T cell isolation and in vitro Treg cell induction. 
Naïve CD4+ T cells were purified from lymph nodes and spleen according to the 
protocol provided by the manufacturer (Invitrogen, catalog no. 11461D). Plates were 
coated with 10 μg/ml of anti-mouse CD3ε antibody (BioLegend catalog no. 100314) for 
4h at 37°C. Before plating the cells, plates were washed once with PBS. Naïve CD4+ T 
cells were suspended at the concentration of 2 x 106/ml in X-Vivo15 serum-free 
medium (Fisher Scientific, catalog no. 04-744Q) with 2 μg/ml anti-mouse CD28 
antibody (BioLegend catalog no. 102112) in the presence or absence of mouse TGF-β 
(BioLegend catalog no. 763102). Cells were cultured for 5 days before the collection 
for RNA and immunoblot analysis 163. 
2.4.4 Treg cell purification and expansion.  
CD4+CD25+ Treg cells were purified from mouse lymph nodes and spleen 
according to the protocol provided by the manufacturer (Invitrogen, catalog no. 
11463D). Treg cells were expanded according to the Treg Expansion Kit protocol 
(Miltenyi Biotec, catalog no. 130-095-925).  Treg cells were treated with 0.5 μM 4-
Hydroxytamoxifen (4-OHT) (Millipore Sigma, catalog no. H7904) for 3 days and 100 
μg/ml cycloheximide (CHX) (Millipore Sigma, catalog no. C7698) as indicated. To 
determine the purity, Treg cells were assessed by flow cytometry and immunoblot 
analysis. 
2.4.5 Flow cytometry 
For surface markers, cells were stained in PBS containing 0.5% (wt/vol) BSA 
with relevant antibodies at 4 °C for 30 min. For analysis of intra- cellular markers, cells 
were first fixed with Fixation/Permeabilization buffer (ThermoFisher, catalog no. 00–
5123) at 4 °C for 30 min and then stained in Per- meabilization Buffer (ThermoFisher, 
catalog no. 00–8333) with relevant antibodies at 4 °C for 30 min. For detection of 
Annexin V population, cells were suspended in 100 μl 1× Annexin V binding buffer after 
surface staining, added 5ul APC-Annexin V at room temperature for 15 min, and then 
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added 400 μl 1× Annexin V binding buffer for flow cytometry measurement. For pY-
STAT5 signaling detection, lym- phocytes were stimulated with IL-2 (0.5 ug/ml in PBS) 
(BioLegend, catalog no. 575402) at 37 °C for 20 min, fixed with 3% Paraformaldehyde 
(formaldehyde) aqueous solution (Electron Microscopy Sciences, catalog no. 15710) at 
1:1 ratio at room temperature for 10 min, washed with PBS, resuspended in 100% cold 
methanol at 4 °C for 10 min and finally stained with antibodies for FACS. For 
intracellular cytokine staining, cells were stimulated with PMA (50 ng/ml, Sigma, 
catalog no. P1585) and Ionomycin (500 ng/ml, Sigma, catalog no. I3909), together with 
GolgiPlug (BD Biosciences, catalog no. 555029) for INFγ, IL-5, IL-13, and IL- 17A or 
GolgiStop (BD Biosciences, catalog no. 554724) for IL-4 at 37 °C for 5 h before being 
stained. Antibody information were shown in Supplementary Table 2. Flow cytometry 
data were acquired on BD Fortessa X-20 and analyzed with FlowJo (v10.5.3). 
2.4.6 Suppression assay 
Naïve human PB tTreg (CD4+CD25+CD127-CD45RA+) were sort-purified from 
PB mononuclear cells (PBMNCs) (Ficoll-Hypaque, Amersham Biosciences) in a two-
step procedure in which CD25+ cells were initially enriched from PBMNCs by 
AutoMACS (PosselD2) with GMP grade anti-CD25 microbeads (Miltenyi Biotec). 
CD25high cells were stained with CD4, CD8, CD25, CD127 and CD45RA and sorted via 
FACSAria as CD4+, CD8−, CD25high, and CD127−CD45RA+. Note that the bead-bound 
and fluorochome-conjugated anti-CD25 antibodies recognize different epitopes 
(Miltenyi Biotec), followed by sorting on a FACSAria (BD Biosciences).  
Purified naïve tTreg were stimulated with a K562 cell line engineered to express 
CD86 and the high-affinity Fc receptor (CD64) (37) (2:1 tTreg/KT), which had been 
irradiated with 10,000 cGy and incubated with anti-CD3 mAb (Miltenyi Biotec). In some 
experiments, tTregs were stimulated with KT64/86 cells that were preloaded, 
irradiated, and frozen (1:1 tTreg/KT). Naive tTreg were cultured in X-Vivo-15 
(BioWhittaker, Walkersville, MD) media supplemented with 10% human AB serum 
(Valley Biomedical), Pen/Strep (Invitrogen), and n-acetyl cysteine (USP). Recombinant 
IL-2 (300 IU/mL; Chiron, Emeryville, CA) was added on day 2 and maintained for 
culture duration. Cultures were maintained at 0.25 x 106 to 0.5 x 106 viable nucleated 
cells/ml every 2 to 3 days. On day 14, tTreg and CD4+ Teff were aliquoted and frozen. 
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When needed, frozen tTreg were thawed and re-stimulated with anti-CD3/CD28 mAb-
coated Dynabeads (Life Technologies, Carlsbad, CA) at 1:3 (cell to bead) ratios in the 
presence of recombinant IL-2 (300U/ml). OGA inhibitor (10 μM) was added to re-
stimulated tTreg cultures on day 0 and day 4. tTreg were cultured a total of 7 days 
following re-stimulation and were then harvested for flow phenotyping and suppressive 
function. 
The in vitro suppressive capacity of expanded tTregs was assessed with a 
CFSE (Carboxyfluorescein succinimidyl ester) inhibition assay as previously published 
164,165. Briefly, PBMNCs were purified, labeled with CFSE (Invitrogen), and stimulated 
with anti-CD3 mAb-coated beads (Dynal) ± cultured tTreg (1:2 to 1:8 tTregs/PBMC). 
On day 4, cells were stained with antibodies to CD4 and CD8 and suppression was 
determined from the Division Index (FlowJo, TreeStar). tTregs suppressed CD4 and 
CD8 T cell responses equivalently and only CD8 data were presented.  
2.4.7 Cell culture and transfection 
HEK 293T cells were cultured in DMEM with 10% fetal bovine serum (FBS). 
TMG (CarboSynth, 10 μM), ST045849 (TimTec, 100 μM), MG132 (Cayman, 20 μM), 
and cycloheximide (Sigma, 100 μg/ml) were treated as indicated. The mouse FOXP3-
Myc/DDK plasmid was purchased from OriGene (MR227205). Point mutants of FOXP3 
were generated with the QuikChange XL II Site-Directed Mutagenesis Kit (Agilent). 
pCMV-Myc-human OGT and 3xFlag/2xMyc-OGA were kindly provided by Dr. Xiaochun 
Yu at University of Michigan and Dr. Xiaoyong Yang at Yale University, respectively. 
FOXP3-Myc/DDK was subcloned into the 3xFlag/2xMyc empty vector to construct the 
3xFlag/2xMyc-FOXP3-Myc/DDK plasmid. IL-2 promoter luciferase (#12194) and pIS1 
(#12179) were from Addgene. Cells were transfected with FuGENE HD (Promega) 
according to manufacturer’s instructions. 
2.4.8 FOXP3 protein purification, in-solution digestion, and mass 
spectrometry 
3xFlag/2xMyc-FOXP3-Myc/DDK and Myc-OGT were co-transfected into 5x 
15cm-dishes of 293T cells and purified by immunoprecipitation with M2 Flag beads 
(Sigma) followed by 3xFlag peptide (Sigma) elution according to established 
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procedures 126. IP eluates were denatured in 0.2% Rapigest SF (Waters), reduced with 
5 mM DTT, alkylated with 10 mM Iodoacetamide, and finally digested overnight at 37°C 
with 5% (w:w) sequencing grade Trypsin (Promega). Digests were acidified with formic 
acid for 30 mins to degrade the Rapigest and peptides were then recovered and 
desalted with C18 OMIX tips (Agilent).  
Tryptic peptides were analyzed by on-line LC-MS/MS using an Orbitrap Fusion 
Lumos (Thermo) coupled with a NanoAcquity UPLC system (Waters). Peptides were 
separated over a 15 cm x 75 μm ID 3 μm C18 EASY-Spray column (Thermo). 
Precursor ions were measured from 350 to 1800 m/z in the Orbitrap analyzer 
(resolution: 120,000; AGC: 4.0e5). Ions charged 2+ to 8+ were isolated in the 
quadrupole (selection window: 1.6 m/z units; dynamic exclusion window: 30 s; MIPS 
Peptide filter enabled), fragmented by EThcD (Maximum Injection Time: 250ms, 
Normalized Collision Energy: 25%) and measured in the Orbitrap (resolution: 30,000; 
AGC; 5.0e4). The cycle time was 3 seconds. 
Peaklists were generated using PAVA (UCSF) and searched using Protein 
Prospector 5.23.0 against the human SwissProt database (downloaded 9/6/2016) and 
a randomized concatenated database with the addition of the recombinant FoxP3 
recombinant sequence. Cleavage specificity was set as Trypisn allowing 2 
miscleavages. Carbamidomethylation of Cys was set as a constant modification and 
two of the following variable modifications were allowed per peptide: acetylation of 
protein N-termini, oxidation of Met, oxidation and acetylation of protein N-terminal Met, 
cyclization of N-terminal Gln, protein N-terminal Met loss, protein N-terminal Met loss 
and acetylation, acetylation of Lys, phosphorylation of Ser, Thr, Tyr, HexNAc on Asn 
within the N glycan motif (NXST), HexNAc on Ser, Thr, Tyr, and PhosphoHexNAc on 
Ser or Thr. Precursor mass tolerance was 20ppm and fragment mass tolerance was 30 
ppm. Phosphorylated and HexNAcylated peptides were manually verified.  
2.4.9 RNA and real-time PCR  
Total RNA was extracted using RNeasy Plus Universal Kits (QIAGEN, catalog 
no. 73404). cDNA was reverse transcribed (BIO-RAD, catalog no. 170-8891) and 
amplified with SYBR Green Supermix (BIO-RAD, catalog no. 172-5124). All data were 
normalized to the expression of 18S. Primer sequences are available on request. 
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2.4.10 Immunoprecipitation and Western blotting  
Anti-O-GlcNAc (Abcam, catalog no. ab2739), anti-FOXP3 (eBioscience, catalog 
no. 56-7773-82), anti-c-Myc (SANTA CRUZ, catalog no. sc-40), anti-Flag (Millipore 
Sigma, catalog no. F3165), anti-β-Actin (Millipore Sigma, catalog no. A5441) antibodies 
were used. For Immunoprecipitation, whole-cell lysates were precipitated by anti-FLAG 
M2 Affinity Gel (Millipore Sigma, catalog no. A2220). Cells were lysed in buffer 
containing 1% Nonidet P-40, 50 mM Tris 3 HCl, 0.1 mM EDTA, 150 mM NaCl, 
proteinase inhibitors and TMG. Equal amounts of protein lysates or 
immunoprecipitation samples were electrophoresed on 8% SDS-PAGE gels and 
transferred to PVDF or Nitrocellulose membranes. Primary antibodies were incubated 
at 4 °C overnight. Western blotting was visualized by peroxidase conjugated secondary 
anti- bodies and ECL chemiluminescent substrate or by 800CW infrared fluorescent 
IgG secondary antibodies imaged on a Bio-Rad ChemiDoc Imaging System or a LI-
COR Odyssey 9120 infrared imager, respectively.  
2.4.11 Retroviral transduction  
STAT5A, constitutively active (CA)- STAT5A, and O-GlcNAc-deficient CA-
STAT5A-T92A retroviral expression plasmids were kindly provided by Dr. Richard 
Moriggl at University of Veterinary Medicine, Vienna. Wildtype and mutant FOXP3 
were constructed into the pMSCV-IRES-eGFP retroviral vector. Retrovirus were 
packaged in 293FT cells and viral supernatants were harvested for use. Treg cells 
were cultured 48 h, then spin infected with viral supernatants (2500 rpm, room 
temperature for 2 h) in the presence of 8 μg/ml polybrene 166. Cells were cultured for 
another 3 days. 
2.4.12 RNA-seq  
Treg cells were isolated from female Foxp3YFP-Cre/wtOgtfl/fl and Foxp3YFP-
Cre/wtOgtwt/fl mice using CD4 selection beads (ThermoFisher, 11461D) followed by 
sorting on YFP expression. RNA was extracted using the RNeasy Plus Micro Kit 
(QIAGEN, catalog no. 74034) and subjected to library construction and 2x50 paired-
end sequencing on a HiSeq 2500 (Illumina) at the University of Minnesota Genomics 
Center. Sequencing reads were trimmed (Trimmomatic v0.33), quality control checked 
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(FastQC), mapped (bowtie2 v2.2.4.0), and quantified for gene expression (Cuffquant). 
Differentially expressed genes were determined by EdgeR. Pathway analyses and 
upstream regulator analyses were performed using Ingenuity Pathway Analysis 
(Qiagen). 
2.4.13 Data availability  
RNA Sequence data that support the findings of this study have been deposited 
in Gene Expression Omnibus with the accession number GSE116758. Mass spectra 
data can be accessed on MS-Viewer 167 with the key: artnlq2gpq.  
2.4.14 Statistical analyses 
Results are shown as mean ± SEM. Comparisons were carried out using a two-
tailed Student's t-test, one-way ANOVA followed by Tukey’s multiple comparisons test 
or two-way ANOVA followed by Tukey’s multiple comparisons test. Survival curves 
were done using the Kaplan-Meier method and compared with a logrank test. 
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Chapter 3 AIRE drives early life thymic 





Interferons provide a robust first line of defense against invading pathogens. 
Specifically, Type I IFNs (IFN-I) are highly and transiently induced upon viral infection, 
during which they activate intracellular programs that promote innate immunity and 
activate adaptive immune responses 168. We found in a previous work, that medullary 
thymocytes had a distinct interferon stimulated gene (ISG) signature 169, which 
suggests that interferons might be constitutively produced in the thymus. This ISG 
signature was abrogated in thymocytes lacking the IFN-I receptor gene, Ifnar1, 
showing a direct role of IFN-I signaling in the thymus. Indeed, there is evidence of IFN-
β (a subtype of IFN-I) being produced in the thymus at low levels during the steady 
state 170,171. 
 
While the evidence for thymic IFN-I is clear, other related aspects such as the 
IFN-I cellular source, the cell populations responding to IFN-I and their effect on the 
thymic microenvironment remain uncertain. Lienenklaus et al. showed that thymic IFN-
β expression was dependent on Aire and indicated that mTEC were the main 
producers 171, whereas Otero et al. suggested that IFN-β regulated both the 
development of mTEC and their expression of Aire 170. Thus, there is a need to 
precisely identify the source of IFN-β and determine whether IFN-β is essential for 
development, maintenance, and gene expression of other thymic antigen presenting 
cells. 
 
Previous studies indicated that multiple cells in the thymic microenvironment may 
be responding to IFN-I. Transcriptional studies and mouse reporter experiments 
showed that thymocytes 169,172, mTEC 171 and thymic dendritic cells (DC) 71 express 
ISG. However, there is confusion about the fraction of the cell populations responding 
to IFN-I and their dependency on the IFN-I receptor. For instance, thymic Ifnar1-
deficient DCs still displayed a strong ISG signature 71. Thus, it is essential to examine 
in more detail which populations are receiving IFN signaling in the steady state and 
which receptors are employed by cells to receive those signals.   
 
In this study, we used various cytokine expression and cytokine signaling 
reporter mice, as well as RNAseq to address these questions. We found that IFN-β 
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was mainly produced by a very small number of MHC-II+ mTEC (mTEChi) in an AIRE-
dependent manner. Furthermore, we demonstrated that most cells in the thymic 
microenvironment respond to both IFN-I and IFN-III (IFN), and that these signals 
significantly reshape the thymic microenvironment by regulating the thymic APC 
composition and their overall gene expression. These findings have important 




3.2.1 Developing T cells respond to IFNβ produced by mTEChi cells 
Transcriptional profiling by our lab and others showed that both thymocytes 
169,172 and thymic dendritic cells 173 express a strong IFN-I signature.  Here, we sought 
to characterize this phenomenon in more detail. In thymocytes, the expression of the 
cell surface proteins Qa2 and Ly6A was strongly dependent on IFN-I in both CD4SP 
and CD8SP thymocytes (Figure 3.1). This effect was largely attributable to IFN-β, as 
Qa2 and Ly6A expression was substantially reduced in Ifnb1-/- SP thymocytes, and 
even further so in Ifnar1-/- SP thymocytes. The absence of both Ifnar1 and Ifnlr1, or the 
gene encoding the signal transducer Stat1 completely abrogated the expression of 
Qa2 and Ly6A.  
 
These observations are in line with two previous studies reporting expression of 
IFN-β in the thymus during the steady state 170,171. To identify the cell source of this 
IFN-β, we used a published luciferase mouse reporter (Ifnbluc) 171. After magnetic 
sorting, luciferase activity was mostly detected in the fraction enriched for epithelial 
cells, specifically the fraction expressing CD80 (Figure 3.1b) —mTEChi cells. 
Endogenous Ifnb1 expression measured by qPCR in FACS-sorted thymic cell 





Figure 3.1. Developing T cells respond to IFNβ produced by mTEChi cells 
(a) Representative expression and geometric mean fluorescence intensity (gMFI) of Qa2 and 
Ly6A on mature CD4SP (CD4+ CD8- CD62L+ CD69-) thymocytes from WT, Ifnar1-/-, Ifnb1-/-, 
Ifnar1-/-/Ifnlr1-/-, and Stat1-/- mice (left). Qa2 and Ly6A gMFI of CD8SP (CD4- CD8+ CD62L+ 
CD69-) (right) from 5-6-week-old mice. (b) Luminescence of indicated cell populations from 
thymi of Ifnbluc mice) (c). Ifnb1 expression by qPCR in sorted populations from wild-type 
C57BL/6 mice (n=4) presented relative to that of sorted CD45+ cells from the same experiment. 
Data are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by ANOVA with 
multiple comparisons. 
 
3.2.2 IFNβ expression is AIRE-dependent and expressed by a tiny 
fraction of mTEC 
The two previous studies reporting IFN-β expression in the thymus came to 
contradictory conclusions about its activation. Otero et al. reported that RANKL 
induced Ifnb1 expression in mTEC cells cultured in vitro, and concluded that RANKL 
could directly bind the Ifnb1 gene and promote its expression, as it does in osteoclasts 
170. On the other hand, Lienenklaus et al. proposed that IFN-β expression is an Aire-
dependent process 171. We wanted to test if RANKL regulates Ifnb1 in vivo, but could 
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not examine RANKL deficient mice, as they have strongly impaired mTEC 
differentiation 174–177. Rather, we performed short term RANKL blockade. Two days of 
anti-RANKL treatment resulted in a 2-fold decrease in Ifnb1 expression in Ifnbluc mice 
(Figure 3.2a) without decreasing the total number of TEC cells (Figure 3.2b). However, 
given the importance of RANK-RANKL signaling for mTEC differentiation, we 
examined Aire expression, and noted this RANKL blockade resulted in a 2-fold 
decrease in the number of mTEC cells expressing Aire as well (Figure 3.2c). Thus, we 
tested if Ifnb1 expression was dependent on Aire. Indeed, as suggested by 
Lienenklaus et al. 171, Ifnb1 expression was strongly dependent on Aire, being 
decreased more than 100-fold in mTECs from Aire-/- mice (Figure 3.3a). This was also 
reflected in the low levels of Qa2 and Ly6A expression in SP thymocytes from Aire-/- 
mice (Figure 3.3b and c).  
 
Figure 3.2. RANK-L blockade reduces the number of Aire-expressing mTECs.  
Ifnbluc mice were treated with a control IgG or -RANKL antibody and 48 hours later (a) 
bioluminescence (as measured by average flux in photons/second) from in vivo imaging was 
measured. Data are pooled from 4 independent experiments. (b) Absolute cell numbers of 
indicated populations 48h after treatment. (c) Representative data of expression of Aire by flow 
cytometry in mTEChi 48h after treatment (left). Absolute cell number of Aire+ mTEC (right). Data 
are pooled from 2 independent experiments. Data are shown as mean ± SD. *p<0.05, **p<0.01 
by unpaired t-test (a) and two-way ANOVA with multiple comparisons (d and c). 
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Since many Aire dependent genes are only expressed in a subset of Aire-
positive mTEC 178,179 we wished to characterize Ifnb1 expression at the single cell level. 
Thus, we obtained an Ifnb1-Tdtomato knock-in reporter (Ifnbtom) mouse strain. Flow 
cytometric analysis of thymus of these animals revealed that only a very small fraction 
of mTEChi cells were Tdtomato+ (Figure 3.3d). We did not observe any Tdtomato+ cells 
in the hematopoietic compartment of the thymus (Figure 3.3e). Thus, we favor the 
conclusion that RANKL induces Aire expression in mTEC, a subset of which 
upregulates Ifnb1.  
 
 
Figure 3.3. IFNβ expression is Aire-dependent and expressed by a tiny fraction of mTEC. 
(a) Ifnb1 expression by qPCR in sorted mTEChi from WT and Aire-/- mice (n=2) presented 
relative to WT mTEChi (b) Representative expression of Qa2 and Ly6A on CD4SP thymocytes 
from WT and Aire-/- mice (left); Qa2 and Ly6A gMFI of CD4SP normalized to mean of DP 
(right). (c) Qa2 and Ly6A gMFI of CD8SP normalized to mean of DP. (d) Expression of IFN-
tdTomato in mTEChi (d) or CD45+ cells (e) from IFNWT/WT or IFNKI/KI mice. Data are shown as 
mean ± SD. *p<0.05, **p<0.01, ***p<0.001 by unpaired t-test (b and c) and two-way ANOVA 
with multiple comparisons (d). 
3.2.3 IFNβ expression peaks at 3 weeks of age 
To study the temporal dynamics of Ifnb1 expression in the thymus, we 
evaluated luciferase expression in Ifnbluc mice of different ages. Interestingly, luciferase 
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expression was the highest at around 2-3 weeks of age but remained expressed at low 
levels through adulthood (Figure 3.4a). This age dependence was closely correlated 
with the temporal abundance of Aire+ cells within the thymus for (Figure 3.4b), even 
when corrected for the total number of cells in the thymus. This finding confirms the 
notion that Aire regulates the expression of IFN-β. 
 
Figure 3.4. IFN-β expression changes with age.  
(a) Ifnbluc mice were injected with D-Luciferin at different ages and bioluminescence (average 
flux in photons/second) was measured. Between 1 to 8 mice per time point. Data are shown as 
mean  SD. (b) AIRE+ mTEC as a ratio to CD45+ cells (left axis, circles) or as a proportion of 
TEC (right axis, squares) in various ages of WT C57BL/6 mice. Data are shown as mean  
SEM. 
3.2.4 Most cells in the thymic microenvironment respond to interferons in 
the steady state 
Given that IFN-β is produced constitutively in the thymus, we evaluated which 
cells in the thymic microenvironment are responding to it in the steady state. To do this 
we used a reporter mouse that expresses GFP under the control of the endogenous 
Mx1 locus (Mx1gfp) 180. Mx1 is an ISG induced by both IFN-/β and IFN- 181. We found 
that numerous cells, including DCs, B cells, other myeloid cells and thymocytes were 
GFP+ in these mice, implying they respond constitutively to IFN (Figure 3.5). The 
percentage of GFP+ cells and their mean fluorescence intensity (MFI) was notably 
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higher in the thymus than in the spleen, which indicates that the thymic IFN response is 
stronger than the systemic basal IFN response described previously 180,182,183. This is 
also consistent with the strong luciferase signal in the thymus of Ifnbluc mice.  
 
 
Figure 3.5. GFP expression of thymic and splenic cell populations from Mx1gfp mice. 
Thymus and spleen cells from B6 and Mx1gfp mice were stained for the indicated populations 
and GFP expression was measured by flow cytometry. (a) Representative histograms showing 
GFP expression in indicated cell populations. (b) Ratio of geometric mean fluorescence (gMFI) 
of GFP in the thymus vs. spleen for the indicated populations. 
 
To understand how different IFN signaling pathways are involved in the Mx1 
response in the thymus, we crossed this reporter line to mice lacking Ifnar1 or Stat1 (a 
critical signal transducer of both IFNAR and IFNLR signaling pathways). We found that, 
contrary to what occurs in the spleen, where the basal IFN response is dependent on 
IFN-I 180, the intrathymic IFN response was more complex. GFP expression was absent 
in T cells, pDCs and some myeloid cells in Mx1gfp/Ifnar1-/- mice; however, the response 
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in thymic B cells and DCs was not abrogated unless Stat1 was deficient, indicating that 
both IFN-I and IFN-III are inducing cellular responses constitutively in the thymus.  
 
The percentage of GFP+ B cells did not change in the absence of Ifnar1 but was 
completely abolished in the absence of Stat1, which suggests a potential redundant 
role of IFN-III signaling in this cell population. The IFN response in DCs was more 
heterogeneous with the response being partially dependent on IFN-I in SIRP + DCs, 
and IFN-I-independent in XCR1+ DCs. GFP expression in T cells confirmed their 




Figure 3.6. Thymic cell populations respond to both IFN-I and IFN-III in the steady state. 
Thymus and spleen cells from B6 (WT), Mx1gfp, Mx1gfp/Ifnar1-/- and Mx1gfp/Stat1-/- mice were 
stained for the indicated populations and GFP expression was measured by flow cytometry. (a) 
Representative plots for four of the main cell populations. (b) Summary of the percentage of 
GFP+ cells out of every cell population. 
3.2.5 IFN impacts hematopoietic, but not stromal, APC composition and 
gene expression 
With IFN-I and IFN-III regulating Mx1gfp expression in the thymus, we wondered 
whether this expression had consequences for the population composition of the 
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thymic APC. To evaluate this, we quantified the number of thymic APCs from mice 
lacking IFN-I and/or IFN-III signaling. While the absence of IFNAR did reduce the 
number of pDCs and Ly6C+ monocytes, the rest of the populations remained mostly 
unchanged. However, the absence of both IFNAR and IFNLR, or STAT1, also reduced 




Figure 3.7. Interferon-dependent changes in thymic APC composition. 
Thymus cells from the stromal (a) and hematopoietic (b) compartment B6 (WT), Ifnar1-/-, Ifnar1-/-
/Ifnlr1-/- (DKO), and Stat1-/- mice were stained for the indicated populations and quantified by 
flow cytometry. 
 
IFNs induce the expression of hundreds of genes that reshape the cellular 
response to infections 184. Given that thymic APCs were responding to IFN in the 
Mx1gfp reporter mice, we examined the broader gene expression changes associated 
with this response. To do this, we performed high-throughput RNA sequencing 
(RNAseq) on the major DC subsets (XCR1+, SIRP+ CD301b-, SIRP+ CD301b+) from 
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wildtype, Ifnar1-/-, Ifnb1-/-, Ifnar1-/-/Ifnlr1-/-, and Stat1-/- mice (Figure 3.8). This 
transcriptome analysis revealed a few genes downregulated in the absence of IFNAR, 
which were also identified in the Ifnb1-/- DCs. This indicates that, just as in T cells (see 
Figure 1a), the IFN-I response in DCs is mainly mediated through IFN-β.  
 
 
Figure 3.8. RNA-seq reveals profound changes in gene expression driven by IFNs. 
Thymus cells from WT, Ifnar1-/-, Ifnb1-/- (IFNb-KO), Ifnar1-/-/Ifnlr1-/- (IFNLAR-DRKO), and Stat1-/- 
mice were stained and FACS-sorted for the indicated populations of DCs and their 
transcriptome was examined with bulk RNA sequencing. Heatmaps display unsupervised 
clustering of the normalized expression of genes significantly downregulated in Stat1-/- 
compared to the WT in each DC population. 
 
Furthermore, we found striking changes in the transcriptome of all DCs subsets 
in the absence of STAT1. The magnitude of these gene expression changes was 
significantly larger than the changes found in the absence of IFNAR alone (Figure 3.8). 
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Remarkably the changes in Stat1-/- APC were equivalent in mice that lacked both 
IFNAR and IFNLR, again suggesting that type I and III interferons are involved.  
 
Given the significant effect of IFNs in DC gene expression, we decided to take 
a comprehensive approach to examine the effects of IFNs in all thymic APCs. To do 
this, we performed single-cell RNA sequencing (scRNA-seq) analysis on MHC class II-
expressing thymic cells. We used cell hashing with barcoded antibodies 185, which 
allowed us to multiplex samples from WT, Ifnar1-/- and Ifnar1-/-/Ifnlr1-/- mice and 
simultaneously analyze them in a single run. After processing and doublet removal, we 
obtained 10,743 individual cell transcriptomes with roughly equivalent cell numbers per 
genotype. Dimensionality reduction analysis was performed to visualize the expression 
data and allowed us to identify 14 cell clusters (Figure 3.9a), consistent with the cell 
heterogeneity of the sample. B cells and different subpopulations of conventional DCs 
were identified in the 5 most populated clusters (#0 - 4) and accounted for 
approximately 70% of the whole sample. Cluster 5 contained cells with 
monocyte/macrophage identity (C1q genes, CD68, Mrc1, Mertk, etc.). The remaining 
clusters (#6-13) were identified as apoptotic cells, T cells, eosinophils, neutrophils, 
pDC and TEC. These clusters were expected to be small due to either low expression 
levels of MHC-II (#6-10, 12-13) or inefficient cell recovery with the digestion protocol 
used (collagenase D) (#11). 
 
When the analysis was broken down by cell hashtags, we found that the cells 
from WT and Ifnar1-/- mice tended to cluster together, whereas Ifnar1-/-/Ifnlr1-/- cells 
clustered further from the other two genotypes, indicating their dissimilarity (Figure 
3.9b). This was the case for all the main six clusters (#0-5), as well as #9 and #11. 
Indeed, consistent with the bulk RNA-seq analysis of DCs, the differentially expressed 
gene (DEG) analysis of all the main clusters found only a handful of DEGs between 
WT and Ifnar1-/-, but an extensive list when WT and Ifnar1-/-/Ifnlr1-/- were compared 
(Figure 3.10a). Not surprisingly, the majority of DEGs were ISG (discussed below). 
Representative genes from these two expression patterns are depicted in Figure 3.9c, 
with Ifi27l2a downregulated in the absence of IFNAR alone (except in the B cell 
cluster), and Isg15 expression unchanged in the Ifnar1-/- but almost absent in all the 




Figure 3.9. scRNA-seq profiling reveals profound changes in gene expression by IFN-I 
and IFN-III. 
MHC class II-expressing thymus cells from WT, Ifnar1-/- and Ifnar1-/-/Ifnlr1-/- were FACS-sorted, 
captured with a 3’ Single Cell V5 chemistry platform, and sequenced. Cell hashing was used to 
distinguish the genotypes of origin. (a) UMAP plot from all 10,743 transcriptome events showing 
14 clusters identified. (b) UMAP plot presented in a with information about the genotype of 
origin (c) Normalized expression of selected gene markers in the three different genotypes 
analyzed. 
 
Finally, to further scrutinize these IFN-dependent gene expression changes, we 
created a heat map to visualize the normalized expression of the genes that were 
downregulated by the absence of both IFNAR and IFNLR in at least half of the main 
clusters. Interestingly, we found that in addition to the classic and universally 
expressed ISGs (Stat1, Usp18, Bst2, etc), there were many DEGs whose expression 
tended to be more cell-specific (Figure 3.10a). For example, the absence of 
Ifnar1/Ifnlr1 in B cells resulted in the downregulation of genes involved in B cell 
maturation and activation, like Igha or Iglc1, and consequently relative upregulation of 
genes that promote memory formation over effector differentiation, like Ets1 186 and 
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Bach2 187. In DCs, we noticed many DEGs were associated with antigen processing 
and presentation (Psmb8, Psmb9, Tap1, B2m). 
 
 
Figure 3.10. Thymic IFNs induce the expression of genes involved in antigen processing 
and presentation. 
(a) Heat map displaying unsupervised clustering of the normalized expression of a subset of 
427 genes that were downregulated in Ifnar1-/-/Ifnlr1-/- cells compared to the WT in at least 3 of 
the 6 clusters shown. Exemplary genes of each group with similar gene expression pattern. (b) 
Over-representation analyses against the Gene Ontology database were performed on the lists 
of differentially expressed genes (WT vs. Ifnar1-/-/Ifnlr1-/-) of each cluster and the heat map 
displays the enrichment ratios of the gene sets with FDR<0.05. 
 
Nevertheless, when we did analysis to identify gene sets that were enriched in 
the lists of DEGs of each cluster, we found that most clusters shared the biological 
processes affected by the absence of IFN-I and IFN-III signaling (Figure 3.10b). Of 
note, besides the highly inducible ISGs involved in IFN response, the IFN response in 
B cells and DCs, but not in monocyte/macrophages, was enriched in genes involved in 
antigen processing and presentation. 
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Taken together, these data suggest that IFN-I and, likely IFN-III 188, are 
constitutively being produced in the thymus and drive the expression of hundreds of 
genes in APCs that reshape the thymic microenvironment during T cell development. 
Moreover, thymic IFN signaling plays a vital role in the regulation of antigen processing 
and presentation, which seems likely to promote qualitative changes in the repertoire of 
displayed self-peptides and impact T cell tolerance development (Figure 3.11). 
 
 
Figure 3.11. Proposed model of thymic IFNs during development. 
In our model, a small number of mTEChi cells express both IFN-β and IFN- in an Aire-
dependent manner. These IFNs induce the expression of ISGs on thymic APCs like B cells or 
DCs. IFNs also modify antigen processing and presentation, which regulates the repertoire of 
self-peptide displayed to developing thymocytes. ISG-self-reactive and other self-reactive 







The presence of IFN-I and, more recently IFN-III 188, in the thymus has been 
described but the consequences of this expression on the thymic microenvironment 
are still not clearly defined. In this study, we characterized the expression of IFN-β in 
the thymus and found that it was constitutively expressed by a small number of 
mTEChi cells in an Aire-dependent manner. Importantly, we discovered that thymic 
APCs respond not only to IFN-I but also to IFN-III and that signaling through these 
molecules induces profound gene expression changes that alter the thymic 
microenvironment. 
 
Our results agree with the notion that RANKL signaling can induce the 
expression of IFN-β, however, contrary to published data, we propose that it does so 
indirectly through the upregulation of Aire. The expression pattern of IFN-β resembles 
that of an Aire-regulated gene, with only a reduced number of mTEChi cells producing it 
at any given moment. Notably, although we observed significant changes in the thymic 
hematopoietic APC composition in mice lacking both Ifnar1 and Ifnlr1, the absence of 
IFN signaling (in Ifnar1 or Ifnar1-/-/Ifnlr1-/-) did not dramatically change the TEC 
population composition (Figure 3.7), showing that TEC differentiation is largely 
independent of IFN-I/IFN-III. We did not observe significant gene expression changes 
in the TEC population by scRNA-seq either, but the tissue digestion protocol we used 
did not provide sufficient cell numbers to make conclusions with statistical power. That 
GFP expression was low in TECs in the Mx1gfp mice suggests that, although they are 
the main IFN producers, their IFN responses are not strong. This could be due to 
increased ligand-induced IFNAR internalization as a result of autocrine signaling 189, or 
enhanced expression of negative feedback loop mediators. Indeed, transcriptomics 
data from the ImmGen Consortium show an increased expression of Socs1, Socs3, 
and Usp18 in mTECs compared to thymic DCs—genes that encode negative 
regulators of IFNAR signaling. However, detailed studies that allow for fair 
comparisons between the stromal and the hematopoietic compartments are needed.  
 
The lower expression of MHC-I in TECs from Ifnlr1-/- (but not Ifnar1-/-) mice 
suggests that TECs are constitutively responding to IFN-III 188. Our results suggest that 
thymic B cells and DCs are also responding to IFN-III. This is an interesting finding 
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given the confusing current body of knowledge about the impact of IFN-III on non-
epithelial cell populations (reviewed by Hemann et al. 190). Furthermore, the role of IFN-
III in B cell responses is unclear and thought to occur in humans but not in mice 190, but 
our data argue for a role of IFN-III in murine thymic B cell homeostasis.  
 
The lack of IFN-I/III signaling caused reductions in several thymic hematopoietic 
APC subsets—notably monocytes, B cells, and pDCs. It is not clear if the absence of 
IFN resulted in poor recruitment of these APCs or affected their homoeostatic 
proliferation and survival. From the gene expression changes, we did not see evident 
downregulation of chemokine or cytokine levels, but we did see reduced maturation 
signals in some of the clusters. Whether these signals impacted cell proliferation or 
survival remains to be established. 
 
The broad changes in gene expression driven by IFNs, and the fact that genes 
involved in antigen processing and presentation were altered, suggest that IFNs are 
likely modifying the repertoire of self-peptides displayed by thymic APCs. We found 
that IFN drives the expression of hundreds of ISG in most of the APC populations in 
the thymus, and it is reasonable to think that the proteins encoded by those ISGs will 
be processed and their epitopes presented by MHC molecules, as described for virally 
infected cells 106. Besides, those processes of antigen degradation and loading into 
MHC molecules are themselves stimulated by IFNs, which would result in more and 
different peptides being displayed on their surface. This would have profound 
implications for the establishment of a tolerant repertoire of T cells. Proteomics studies 
addressing this issue are needed to understand how the immunopeptidome of thymic 
APC varies in the presence of constitutive IFN-I and IFN-III. Presumably, the 
interaction of thymocytes with IFN-stimulated APCs would lead to tolerance to the IFN-
dependent changes that occur during some types of inflammation, like a viral infection, 






C57BL/6NCrl (C57BL/6) were purchased from the National Cancer Institute. 
B6.129S2-Ifnar1tm1Agt/Mmjax (Ifnar1-/-), B6.129S(Cg)-Stat1tm1Dlv/J (Stat1-/-), and 
B6.129S2-Airetm1.1Doi/J (Aire-/-) were obtained from Jackson Laboratories. B6.129P2-
Ifnb1tm1Acgp mice (Ifnb1-/-) were kindly provided by E. Fish and have been described 
previously 191. IFNtdTomato (IFNKI/KI) were kindly provided by D. B. Stetson (University 
of Washington). B6.Cg-Mx1tm1.1Agsa/J (Mx1GFP) were kindly provided by A. García-
Sastre (Icahn School of Medicine at Mount Sinai) and have been described previously 
180. IFN-β+/Δβ-luc (-luc) were kindly provided by S. David (University of Minnesota) and 
have been described previously 171. Unless noted, mice were used at approximately 5 
weeks of age. All animal experiments were approved by the Institutional Animal Care 
and Use Committee of the University of Minnesota. All animals were maintained under 
specific pathogen-free conditions at the University of Minnesota. 
3.4.2 Flow Cytometry 
For all cell populations, except thymic epithelial cells (TEC), tissues were first 
injected with 500L Collagenase D (1mg/mL; Roche), then finely chopped in 1mL 
Collagenase D, and incubated for 30 minutes at 37C. The digestion was stopped by 
adding EDTA (Sigma) for a final concentration of 5mM. The suspensions were passed 
through 70μM cell strainers and washed with 5% FBS in RPMI. Single cell suspensions 
in 2% FBS in PBS were blocked with Fc block (anti-CD16/CD32; 2.4G2, Tonbo 
Biosciences) for 15 minutes at 4°C and then stained for 30 minutes at 4C with the 
indicated antibodies (below). Samples were acquired with BD LSR Fortessa™ (BD 
Biosciences) and analyzed with FlowJo version X (FlowJo LLC). 
Thymic epithelial cells were isolated using Liberase TH (Roche) digestion as previously 
described 192. TECs were enriched by panning (also described 192) prior to cell sorting, 
but not for direct flow cytometric analysis. Cells were sorted on a FACSAria (Becton 
Dickinson) and populations were reliably >90% of the target population. 
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3.4.3 Antibodies 
Antibodies purchased from BioLegend: CD4 (RM4-5), CD11c (N418), CD19 
(6D5), CD25 (PC61), CD80 (16-10A1), CD45 (30-F11), CD45.2 (104), CD64 (X54-
5/7.1), CD45R (B220; RA3-6B2), CD90.2 (30-H12), CX3CR1 (SA011F11), CD172a 
(SIRP; P84), CD301b (MGL2; URA-1), CD317 (PDCA-1, BST2; 129C1), F4/80 
(BM8), TCR (H57-597), XCR1 (ZET) Ly-6A/E (Sca-1; [D7]), Ly-51 (6C3), Ly6G (1A8) 
Antibodies purchased from BD Biosciences: CD4 (GK1.5), CD8a (53-6.7), CD69 
(H1.2F3), TCR (H57-597), CD86 (GL1), CD90.2 (30-H12), Siglec F (E50-2440), 
EpCAM (G8.8).  
Antibodies purchased from Thermo Fischer: MHC Class II– I-A/I-E (M5/114.15.2), 
Ly6C (HK1.4), FOXP3 (NRRF-30 and FJK-16s), Aire (5H12). 
3.4.4 Cell Isolation and RNA preparation 
Thymic epithelial cells and thymic dendritic cell (DCs) subsets were isolated 
from mice of the indicated genotypes. Briefly, for thymic DCs, thymus digested with 
Collagenase D was stained with Biotin-CD90.2 and was negatively enriched using anti-
streptavidin microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. 
CD90.2- thymocytes were surface stained with indicated antibodies and were 
separated into three subsets with a FACSAria (BD Biosciences). An RNeasy micro kit 
(Qiagen) was used to isolate RNA obtained from each sample per the manufacturer’s 
instructions.  
3.4.5 Bulk RNA sequencing and analysis 
RNA sequencing was performed by the University of Minnesota Genomics 
Center. Total RNA was quantified using a RiboGreen assay. RNA quality was 
assessed via Agilent BioAnalyzer (Agilent Biotechnologies). Library creation was 
performed using the SMARTer Stranded Total RNA Pico Mammalian v2 kit (Takara 
Bio), according to manufacturer’s instruction. Sequencing was performed on a 
NovaSeq6000 using paired-end 150-base chemistry at the University of Minnesota 
Genomics Center. 
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3.4.6 scRNA-sequencing and analysis 
 Sequencing and initial analyses were done at the UMGC of the University of 
Minnesota. MHC-II-expressing thymic cells were captured using the 10x Genomics 3’ 
Single Cell V3 chemistry platform and sequenced in a NovaSeq. Raw sequencing data 
were processed using CellRanger (v 4.0.0). Cellranger ‘count’ was used to obtain gene 
and protein count data for all cells. Count tables were generated for the mRNA and 
HTO data. 
 Raw count data were loaded into R (v 4.0.0) and analyzed with the Seurat R 
package (v 3.2.2). The mRNA expression data were normalized using a log 
normalization method in which feature counts for each cell were divided by the total 
count for that cell and multiplied by a scale factor. A subset of 2000 highly variable 
features (that is, genes that are highly expressed in some cells and lowly expressed in 
others) was identified using the ‘FindVariableFeatures’ function from the Seurat 
package. The HTO count data were added into the dataset and normalized using a 
centered-log ratio method. The Seurat function ‘HTODemux” was used to identify 
‘doublet’ cells.  
 Principal components analysis was performed using the Seurat function 
‘RunPCA’ and a two-dimensional representation of the data was generated using the 
RunUMAP Seurat function. Cells were clustered using the Seurat ‘FindNeighbors’ and 
‘FindClusters’ functions. In the ‘FindClusters’ function, different resolution values were 
tested and resolution value of 0.1, which identified 14 clusters, was chosen.  
Differentially expressed genes were identified between treatment groups within the six 
largest clusters identified above. A Wilcoxon Rank Sum test was implemented in the 
‘FindMarkers’ function in Seurat to identify differentially expressed genes.  
3.4.7 Luciferase assays 
For ex vivo luciferase measurement of populations from Ifnbluc mice, MACS 
separation columns were used (Miltenyi Biotech): depletion with CD45 microbeads was 
followed by CD80 enrichment (labeling with PE conjugated CD80, anti-PE 
microbeads). Samples were treated with cell culture lysis buffer (Promega), and 
luciferase activity was measured in a luminometer (Berthold) using the luciferase assay 
system following the manufacturer’s protocol (Promega).  
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For in vivo imaging, mice were injected i.p. with D-luciferin in PBS (Goldbio), 
anesthetized using Isoflurane (Piramal) and analyzed using a Xenogen IVIS 100 
imaging system (Caliper, a PerkinElmer company). Photon flux was quantified using 
Living Image (Caliper). 
3.4.8 Quantitative RT-PCR (qPCR) 
RNA from sorted cells was extracted using an RNeasy mini kit (Qiagen). cDNA 
was produced using SuperScript III First Strand Synthesis SuperMix (Invitrogen). 
FastStart Universal SYBR Green Master (Roche) and an ABI PRISM 7900HT 
sequence detection system (Applied Bioscience) were used for amplification and 
detection. Gapdh was used for normalization of samples. Primers for Ifnb1 were 
forward: CCC TAT GGA GAT GAC GGA GA, reverse: CTG TCT GCT GGT GGA GTT 
CA. 
3.4.9 Statistical Analysis 
Comparisons of two data sets were carried out using a two-tailed unpaired 
Student's t-test. For comparison of three or more data sets, ordinary one-way ANOVA 
with Tukey’s multiple comparisons test was used. P-values less than 0.05 were 
considered significant. Sample size, experimental replicates, and additional details are 
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